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ABSTRACT
THE REGULATION OF THE TRANSFERRIN RECEPTOR 
BY INDUCERS OF CELLULAR DIFFERENTIATION 
AND BY ANTISENSE PHOSPHOROTfflOATE OLIGODEOXYNUCLEOTIDES
P eter T.C. Ho 
Yale University 
1990
Modulation of surface transferrin receptor (TfR) activity has been associated 
with leukemia cell differentiation and proliferation. To examine the mechanisms 
involved in regulating this event, surface receptor protein and mENA levels were 
measured in HL-60 promyelocytic leukemia cells induced to differentiate along the 
myelocytic and monocytic pathways. Surface TfR down-regulation which occurs 
during granulocytic differentiation by dimethylsulfoxide, retinoic acid, or 
aclacinomycin A appears to be kinetically compatible with reduced biosynthesis 
resulting from reductions in the level of steady-state mRNA. In contrast, 
biosynthetic modulation does not appear to mediate the initial surface receptor 
down-regulation seen during 12-0-tetradecanoylphorbol-13-acetate-induced 
macrophagic differentiation. However, a reduction in levels of receptor message 
appears to contribute to the maintenance of diminished surface TfR activity in 
these 12-0-tetradecanoylphorbol-13-acetate-treated cells. The down-regulation of 
surface TfR, in contrast, is not an early event during monocytic differentiation by 
la,25-dihydroxyvitamin D3. This apparently anomalous observation may be 
explained by the fact that this agent does not induce "terminal differentiation" by 
its strictest definition, since induced cells may not exhibit the loss of proliferative 
capacity.
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A common feature of myelocytic and monocytic differentiating cells is the 
complete inhibition of cellular proliferation observed within 10 to 16 hours 
following a four-fold reduction in surface TfR. We conclude that the early decline 
in surface TfR levels precludes its regulation as a consequence of the decrease in 
proliferation, but rather implicates its role in the programmed cessation of growth 
which is requisite for the terminal differentiation of these cells. Thus, the TfR 
appears to be an important component of the genetic changes underlying leukemic 
cell differention; however, its precise role within this framework of cellular 
mediators and processes critical to the maturation process remains to be fully 
elucidated.
One potential strategy to probe the role of TfR in leukemia cell 
differentiation involves the use of specific agents which, ideally, modulate the 
cellular homeostasis of TfR, but lack disparate biochemical activities within the 
cell. Antisense oligodeoxynucleotides, which have emerged as novel and specific 
inhibitors of gene expression, seem uniquely suited for this purpose. A series of 
phosphodiester and phosphorothioate antisense oligonucleotides were synthesized 
against the human TfR. The phosphorothioate analogues exhibited marked 
biological efficacy in culture, as assessed by inhibition of surface TfR content and 
HL-60 growth, whereas their unmodified phosphodiester counterparts were 
ineffective. Phosphorothioate oligonucleotides were more resistant to hydrolysis by 
serum and cellular nucleases, and were more readily taken up by cells than the 
phosphodiesters, thus providing a partial explanation for the differences in 
biological activity. A length effect was observed, with antisense 30-mers exhibiting 
greater TfR inhibitory activity than 17-iners. The degree of surface receptor 
inhibition observed, however, was not strictly sequence dependent. This suggested 
that the phosphorothioate oligonucleotides may be biologically active in eukaryotic 
cells by processes other than classical antisense complementary binding to mRNA.
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INTRODUCTION
The study of leukemia cell differentiation serves two distinct purposes. 
First, it enhances the understanding of the endogenous process of cellular 
maturation. Second, it may expedite the development of an alternative means of 
cancer chemotherapy based upon the mimicry of the natural process of cellular 
maturation and senescence rather than cytodestruction. The latter objective, 
however, requires that the cellular processes critical to the induction of 
differentiation be first identified and characterized. Down-regulation of the 
transferrin receptor (TfR) has been proposed to be such a process. The expression 
of this receptor, in addition to regulating intracellular iron homeostasis, appears 
to modulate cellular growth and differentiation and is affected by a host of positive 
and negative regulatory elements. It is unclear, however, whether the down- 
regulation of TfR, a common feature seen during the induction of differentiation 
of a variety of model systems, is an event crucial for phenotypic maturation. 
Alternatively, this event may underlie the cessation of proliferation which is, by 
definition, part of the terminal differentiation process. The elucidation of this 
question requires more specific agents than the commonly used inducers of 
differentiation which have pleiotropic actions. An ideal agent should modulate TfR 
expression alone without affecting other cellular processes. Antisense 
oligodeoxynucleotides are appropriate candidates for such analyses since they may, 
in theory, be directed against the expression of a single gene within a cell.
Historical Aspects of the  HL-60 Cell l in e .
The HL-60 cell line has served as one of the primary model systems for in 
vitro studies of cell proliferation and differentiation since its isolation from a 35-
1
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year old leukemia patient over ten years ago (1). Although originally classified 
as an acute promyelocytic leukemia (FAB class M3), more recent evaluation of the 
original histological specimens suggests a more proper classification of "acute 
myeloblastic leukemia with maturation" (FAB class M2) (2). Regardless of the 
pathological taxonomy, the importance of this cell line as a biological model system 
is underscored by its over 700 citations in the literature including two recent 
reviews (3,4).
The phenotypic attributes of HL-60 cells are well defined. These cells grow 
in suspension culture with a doubling time of 20 to 45 hours. The line is 
characterized by a myeloblastic or promyelocytic morphology with large blast-like 
nuclei and a basophilic cytoplasm containing azurophilic granules. Histochemically, 
uninduced HL-60 cells stain positively for myeloperoxidase and acid phosphatase. 
At the surface membrane level, cells express receptors for transferrin, insulin, and 
complement. The importance of transferrin and insulin receptor expression is 
denoted by the fact that HL-60 cells can proliferate and differentiate normally in 
serum-free media formulations provided that insulin, transferrin, and selenium are 
present.
The nuclear composition of HL-60 cells is clearly abnormal with a variety 
of genetic anomalies reported. Its chromosomal ploidy shows marked subline 
variability with monosomic, trisomic, and tetrasomic karyotypes seen. One of the 
most intensely studied genetic alterations and also the first observed in HL-60 cells 
is a marked amplification of the c-myc oncogene (5). Although initially estimated 
as being amplified 30-fold, later analyses indicated extensive subline variability 
with some lines expressing only a 4-fold increase (6). Mutations at two other 
genetic loci with presumed importance to the growth of leukemia cells have been 
found. One allele for the GM-CSF gene is rearranged and partially deleted (7).
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An N-ras oncogene with a point mutation at codon 61 has demonstrated 
transformation potential in the NIH3T3 transfection assay (8).
HL-60 as a  Model System for Cellular D ifferentiation.
One of the most intriguing properties of the HL-60 line is its ability to 
differentiate in response to a diverse variety of natural and synthetic compounds. 
Greater than 90% of the population can mature to either granulocyte-like or 
monocyte/macrophage-like elements depending on the inducing agent employed. 
More detailed discussions concerning the pharmacology of differentiation inducers 
may be found in a recent review by Hickman (9). The in vitro assays which 
confirm lineage-specific cellular differentiation (described in detail below) include 
histology/morphology, the appearance of enzymatic markers or membrane proteins, 
and biological behavior.
One maturation pathway available to HL-60 cells is along the granulocytic 
lineage. Classically, the most commonly used inducers of this pathway are the 
polar-planar compound, dimethyl sulfoxide (DMSO) (10, reviewed in Ref. 11), and 
the vitamin A analogue, fl-all-trans-retinoic acid (RA) (12). Other agents in this 
category include 6-thioguanine (13), methotrexate (14), actinomycin D (12, 13), and 
the anthracyclines, aclacinomycin A and marcellomycin (15). Cells induced by the 
above agents exhibit incomplete maturation toward granulocytes as evidenced by 
Wright-Giemsa staining which reveals a population of metamyelocytes and band 
cells rather than fully differentiated polymorphonuclear neutrophils. Nevertheless, 
these compounds do induce terminal differentiation of HL-60 cells since induced 
cells irreversibly lose their proliferative capacity.
The second maturation pathway available to HL-60 cells is along the 
monocyte/macrophage lineage. The commonly used inducers in this group include
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the phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA) (16, reviewed in Ref. 
17), and the vitamin, la,25-dihydroxyvitamin Ds (18). Although commonly thought 
to be equivalent since both are identified by the appearance of non-specific esterase 
(NSE) activity, macrophagic and monocytic differentiation are phenotypically quite 
distinct. In direct contrast with la,25-dihydroxyvitamin D3-induced monocyte-like 
cells, TPA-induced macrophage-like cells rapidly acquire adherence to plastic, but 
do not exhibit nitroblue tetrazolium (NBT) reducing capacity. In addition, TPA- 
treated cells rapidly lose proliferative capacity, whereas monocytic HL-60 
maturation is not necessarily accompanied by the loss of growth potential, hence 
cannot be definitively designated as "terminal differentiation."
It has been noted previously that substantial subline variability with regard 
to many parameters exists in the HL-60 line. The biological response to inducers 
of differentiation is no exception. Some clones have shown equivalent response to 
optimal concentrations of DMSO or RA (12). Other groups report 90% 
differentiation with DMSO, but only 60% maturation with RA (4). Still other 
groups show a greater response to RA than DMSO.
The plethora of assays and biological events characteristic of each lineage 
of HL-60 differentiation has been summarized by Collins (3). Classically, the 
appearance of NBT activity heralds granulocytic or monocytic differentiation. In 
this assay, mature cells respond to the addition of TPA with a respiratory burst 
characterized by the conversion of oxygen to superoxide anion; this allows reduction 
of the dye, nitroblue tetrazolium, to an insoluble blue/black formazan salt. The 
induction of NSE activity is used to assess monocytic or macrophagic 
differentiation. This histochemical assay, in contrast with its name, is quite 
specific for macrophages which respond with pink/red cytoplasmic staining. The
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kinetics of the appearance of these differentiation markers may vary according to 
the inducer employed.
A variety of events occur at the cell membrane during cellular maturation. 
Transferrin receptor down-regulation is a hallmark of terminal differentiation, 
regardless of lineage. The Fc and complement receptors are typically increased 
with granulocytic, monocytic, or macrophagic maturation. Chemotactic receptors 
increase with granulocytic and monocytic induction, but are lost in macrophage­
like cells. The insulin receptor increases with monocytic differentiation, but 
declines during granulocytic differentiation. Finally, differentiation can be assessed 
by functional criteria reminiscent of the completely mature normal cellular 
counterpart. Macrophage-like cells adhere to plastic. HL-60 induced along the 
granulocyte, monocyte, or macrophage pathways acquire the ability to phagocytose 
latex beads or yeast particles.
O ther Model Systems of Cellular Differentiation.
The complexity and ubiquity of the differentiation process has spawned the 
development of other model systems in addition to the HL-60 cell line. The U- 
937 cell line (19) which matures along the macrophage lineage in response to TPA, 
and the K-562 cell line (20) which can be induced along the erythroid pathway by 
hemin are additional examples of inducible human leukemias. The Friend 
erythroid (21), the WEHI-3B D+ monomyelocytic (22), and the Ml myeloid (23) 
leukemia cell lines are examples of murine differentiation models. Although solid 
tumors represent the more common clinical oncological entities, they are 
underrepresented in terms of in vitro models of differentiation. Nevertheless, 
established cell lines derived from embryonal cell carcinomas, neuroblastomas, 
melanomas, adenocarcinomas, and squamous cell carcinomas have been developed
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for the study of differentiation (24). More detailed discussions of in vitro 
differentiation systems may be found in the following reviews by Schwartz and 
Wiernik (25), Dexter and Spooncer (26), and Sachs (27).
The HL-60 cell line has proven to be a useful model with which to study 
the phenomenon of and mechanisms involved in chemically-induced cellular 
differentiation. Although a variety of agents have been demonstrated to induce the 
maturation of these cells to more mature granulocyte-like, monocyte-like, or 
macrophage-like elements, the mechanism(s) underlying these events is unclear. 
This myriad of differentiation inducers, in addition to their diverse biological 
effects, must, at some point, affect critical cellular processes which prompt cells 
along an irreversible program toward differentiation. The identification of such 
processes will aid in the understanding of the phenomenon of differentiation and, 
perhaps, enhance the ability to effect it.
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Cellular Biology of the  T ransferrin  Receptor.
Iron is an essential co-factor in diverse biological processes, including 
electron transfer, oxygen transport, and catalytic reactions. Thus, the acquisition 
and sequestration of iron is integral for cell viability at the prokaryotic and 
eukaryotic levels. Transferrin, the major serum iron-binding glycoprotein present 
at 0.4 g per 100 ml of blood in man, is requisite for cellular growth in vitro. 
Accordingly, in virtually all serum-free media formulations, transferrin is an 
obligatory component (28,29). Thus, transferrin may be considered a growth factor. 
The transduction of growth modulatory signals from this ligand occurs via the 
transferrin receptor (TfR), a dimeric glycoprotein of Mr 180,000 (reviewed in Refs. 
30,31).
Structurally, TfR consists of identical subunits linked by a disulfide bond. 
The bulk of the receptor exists extracellularly; trypsin treatment of whole cells 
generates a 70 kD fragment which retains transferrin binding properties. The 
transmembranous and intracellular domains of this protein are 20 kD and 5 kD 
in mass, respectively. The polypeptide chain of TfR differs from typical membrane 
proteins in that it lacks a signal peptide leader sequence and it is oriented with 
the N-terminus facing intracellularly. The receptor is post-translationally modified 
with three N-asparagine-linked oligosaccharides, two of which are of the mannose- 
rich type and the other being of the complex type (32). Heterogenous glycosylation 
at these sites has been suggested as the reason for the characteristic appearance 
of TfR as a doublet in certain cell lines on denaturing polyacrylamide gels (33). 
Fatty acid acylation has been demonstrated on TfR, although the biological 
implications of this event are unknown (34,35). The cytoplasmic portion of the 
receptor contains serine residues which serve as substrates for phosphorylation by 
protein kinase C and is thought to mediate receptor internalization.
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The cellular physiology of transferrin uptake via TfR (Fig. 1) displays unique 
properties compared with other receptor-mediated endocytosis systems (36,37). 
Receptor-mediated endocytosis usually results in the delivery of ligand or receptor 
or both to the lysosomes for degradation; however, this is not the fate of 
transferrin nor TfR. At physiological pH, diferric transferrin bound to TfR is 
internalized via a clathrin-coated pit mechanism at the cell surface. The receptor- 
ligand complex is routed to the endosomes, whereupon in the acidic mileau, iron 
is released from transferrin for subsequent cellular storage. Apotransferrin, which 
never dissociates from TfR during the internalization process, is finally delivered 
back to the cell surface. At neutral pH, the apotransferrin has low affinity for its 
receptor and is, therefore, released intact to the culture medium for repetitive 
cycles of iron delivery.
Regulation of T ransferrin  Receptor a t the P ro tein  Level.
The regulation of TfR is complex with as many as three distinct conditions, 
including iron status, cellular proliferation, and cellular differentiation, which 
appear to modulate expression of receptor protein. It is most obvious that TfR 
expression can be modulated to maintain intracellular iron homeostasis; receptor 
levels vary inversely with iron availability. When HeLa cells were incubated with 
diferric transferrin or iron salts, a decrease was seen in TfR number, but not 
binding affinity, as assessed by 12EI-Tf binding (38). Conversely, when K562 cells 
were treated with desferrioxamine, an iron chelator, 12EI-Tf binding increased four­
fold (39). This increase in TfR correlated with an increase in receptor biosynthesis 
as measured by metabolic labelling with “S-methionine and immunoprecipitation 
Finally, the subculturing of stationary phase cells a t low density results in & 
decrease in intracellular ferritin concentrations and an increase in TfR expression,
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Figure 1. Cellular metabolism of TfR. 1-3: TfR biosynthesis and secretion. 4- 
8: Receptor recycling. 4-9: The transferrin cycle. 4-6,10: Lysosomal pathway of 
receptor-mediated endocytosis. 1: Biosynthesis of TfR in rough endoplasmic 
reticulum. 2: Processing of TfR in the Golgi. 3: Insertion of TfR into the plasma 
membrane. 4: Transferrin binding to its receptor in coated regions of the plasma 
membrane. 5: Transfer to receptosomes or endosomes. 6: Acid-facilitated 
dissociation of Fe*3, generating apotransferrin. 7: Transfer of transferrin and its 
receptor to tubular elements of the trans Golgi. 8: Reinsertion of receptor into 
the plasma membrane and dissociation of apotransferrin. 9: Iron loading of 
transferrin. 10: Transferrin does not proceed to lysosomes during internalization.
(Reprinted with permission from Plenum Press.)
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suggesting that depletion of intracellular iron pools is a stimulus triggering TfR 
biosynthesis (40).
The association between TfR and cell growth is extensive. The original 
reports of TfR demonstrated that receptor expression was correlated with cellular 
proliferation in a  variety of leukemia and solid tumor cells, as well as of normal 
hematopoietic tissues. The first such evidence was obtained rather serendipitously. 
Characterization of a newly isolated monoclonal antibody, B3/25, by Omary et al. 
(41) in 1980 revealed that its antigen was a surface glycoprotein present on all 
tested human hematopoeitic cell lines and was induced by mitogen stimulation of 
peripheral blood lymphocytes. One year later, the antigen to B3/25 was positively 
identified as the transferrin receptor (42). These results were confirmed and 
extended to include expression in solid tumor cell lines by another group using 
the monoclonal antibody, OKT9, which was found to specifically immunoprecipitate 
TfR (43). Trowbridge and Lopez (44) employed a different monoclonal antibody, 
42/6, which, unlike B3/25, blocked binding of transferrin to its receptor, to inhibit 
the growth in vitro of a human T-cell leukemia line. Surprisingly, this growth 
inhibition could not be overcome by the addition of iron salts to the culture 
medium, suggesting that the function of TfR may not be limited to iron uptake 
alone.
The recent elucidation of the molecular details of T-lymphocyte activation 
have further substantiated the role of TfR in cellular proliferation. Mitogen 
stimulation with phytohemagglutinin or phorbol esters induced sequentially the 
appearance of receptors for interleukin 2 and transferrin before the onset of DNA 
synthesis. Interestingly, anti-TfR antibodies successfully blocked thymidine 
incorporation, whereas antibodies to the interleukin 2 receptor were without
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inhibitory effect once TfR expression occurred. This implied that TfR induction is 
a requisite event during lymphocyte activation (45).
The literature describing the relationship between TfR ana cellular 
differentiation is equally extensive. Modulation of surface TfR activity has been 
seen during cancer cell differentiation in a variety of model systems. Omary and 
Trowbridge’s (41) original inadvertent examination of TfR described the virtual loss 
of the B3/25 antigen on the surface of HL-60 cells upon induction of differentiation 
with DMSO for two days. TfR down-regulation was quickly confirmed in HL-60 
cells induced with RA (43). Moreover, this phenomenon was not limited to the 
HL-60 line; other differentiation-indudble systems, including hemin-induced K562 
cells (46) and dexamethasone-treated Ml cells (47) showed similar results. In 
contrast to the above effects, Friend erythroleukemia cells express 3- and 6-fold 
increases in cellular TfR after 3 and 5 days, respectively, of DMSO-induced 
erythroid differentiation (48). This difference appears to be due to the increased 
biochemical requirement for iron in the synthesis of hemoglobin in mature 
reticulocytes. In addition, cellular enucleation serves as a distinct mechanism for 
terminating replication in erythroid differentiation. Thus, the increase in TfR 
activity in Friend erythroleukemia cells is appears obligatory for the expresssion 
of the mature phenotype.
Terminal differentiation, by definition, involves both the programmed 
cessation of proliferation and the acquistion of the mature phenotype. The 
relationship between these two endpoints is ambiguous. Excepting for Friend cells, 
which require increased iron uptake as part of its maturation program, TfR down- 
regulation is a feature in all differentiating leukemic cell systems. Since TfR 
expression and cellular proliferation are positively correlated, it is unclear whether
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TfR down-regulation is more closely associated with differentiation per se or with 
growth inhibition, which is a requisite part of the terminal differentiation process.
The mechanisms by which the various differentiation inducers modulate TfR 
levels in HL-60 cells have been previously investigated for only two classes of 
compounds, the phorbol esters and the anthracyclines. These agents modulate TfR 
expression by altering two of the receptor’s aforementioned post-translational 
modifications, phosphorylation and glycosylation, respectively. The anthracyclines, 
aclacinomycin A (ACM) and marcellomycin, are potent inhibitors of N-linked 
protein glycosylation (49). These agents have been implicated by our laboratory 
in decreasing transferrin binding during differentiation by inhibiting the formation 
of dolichol-linked oligosaccharide intermediates dining the biosynthesis of new 
receptors (49). However, the evidence for this is indirect, since actual alterations 
in the oligosaccharide chains of TfR molecules have not been demonstrated.
Using the phorbol ester, phorbol dibutyrate, May et al. (50) found a rapid 
decline in 12SI-transferrin surface binding (t*=60 min) consistent with redistribution 
of membrane-associated TfR to internal sites rather than a decrease in total 
cellular TfR. Furthermore, this event was coincident with rapid phosphorylation 
of the receptor which began within 5 min after treatment and reached a maximum 
by 15 min of exposure to phorbol dibutyrate. Subsequently, this group 
demonstrated that TPA was approximately 30-fold more potent than phorbol 
dibutyrate in stimulating receptor phosphorylation and internalization (51). 
Phosphoamino acid analysis of maximally phosphorylated TfR ‘ licated that serine 
was the only residue phosphorylated following phorbol ester treatment. In an in 
vitro reconstitution system employing protein kinase C purified from rat brain, TfR 
phosphorylation was achieved by the combined presence of Caa% phosphatidylserine, 
and a phorbol ester. This provided confirmation that the effects of the phorbol
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esters could be mediated directly by protein kinase C-induced or catalyzed 
phosphorylation of TfR. This synergism between intracellular Caa* and phorbol 
esters, leading to TfR phosphorylation and down-regulation, was subsequently 
demonstrated in intact HL-60 cells, further implicating the involvement of protein 
kinase C (52). This mechanism for phorbol ester action was not limited to HL- 
60 cells, but was demonstrated to occur in K562 cells (53).
Recently, this scheme for phorbol ester action has been challenged by three 
groups. The cloning of the human TfR (discussed below) has permitted the 
application of molecular biological techniques to test the hypothesis of phorbol ester 
action on TfR. Using oligonucleotide-directed mutagenesis, Kuhn et al. (54) created 
mutant TfR cDNA expression vectors in which one of the five potential 
phosphorylatable serine residues in the cytoplasmic domain of the protein was 
changed to either threonine or alanine. Another mutant, containing a deletion of 
the entire serine-rich region of 36 amino acids, was constructed. These were then 
stably transfected into mouse Ltk' cells. Both wild-type and phosphorylation site 
mutant receptors mediated transferrin internalization and iron uptake, in contrast 
to the truncated TfR. The authors concluded that while the cytoplasmic domain 
of TfR was essential for endocytosis, receptor phosphorylation was not a 
requirement for internalization. However, definitive conclusions concerning the role 
of phorbol ester-induced phosphorylation on TfR internalization were limited. 
Although TPA induced wild-type TfR phosphorylation in this system, it failed to 
promote receptor internalization of either endogenous murine TfR or transfected 
human wild-type TfR in Ltk' cells. This may reflect a fundamental difference 
between the human leukemia and the mouse Ltk' cell lines.
Similar conclusions were obtained by a second group which replaced the 
serine-24 residue, the putative site of TfR phosphorylation, with alanine and
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transfected this mutant expression vector into mouse 3T3 cells (55). Again, phorbol 
esters failed to down-regulate endogenous or transfected TfR, even though induced 
phosphorylation of wild-type transfectants was seen. The authors dted cell-specific 
factors rather than sequence differences in the TfR molecules as a potential reason 
for the differential effects between HL-60 and 3T3 cells. A final group transfected 
a TfR expression vector containing the serine-24 residue mutagenized to a glycine 
into CHO cells and reported no effect of TPA treatment on receptor recycling (56).
Although these data appear to contradict the model proposed by May et al. 
(52), application of these results to the leukemia systems may not be appropriate. 
In contrast with differentiating K562 or HL-60 cells, none of these cell lines 
respond to phorbol esters with receptor down-regulation even when examining 
endogenous TfR; the CHO line, in fact, increases surface TfR upon TPA exposure. 
Because of these gross differences in cellular response, the involvement of a protein 
kinase C-mediated phosphorylation of TfR in signalling receptor down-regulation 
may still apply to the leukemia cells.
Molecular Biology of the Transferrin Receptor.
Examination of the biosynthetic regulation of TfR has become possible with 
the cloning of the human and murine variants of this protein. Ruddle et al. (57) 
first described the molecular cloning of the human TfR by using the MOLT-4 
human acute lymphoblastic T-cell leukemia as a source of DNA. They reported the 
TfR gene to span 31 kb and to be organized into 19 exons. Subsequent study of 
the cDNA clone, pCDTR-1, revealed an mRNA of 4.9 kb organized into a 2.8 kb 
fragment at the 5’ end which codes for TfR protein and a 2.1 kb fragment at the 
3’ end consisting of an untranslated sequence of unknown function (58). An open 
reading frame of 2280 nucleotides specified a 760 amino acid polypeptide with a
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calculated molecular weight of 84,910 dal tons. These data were confirmed by 
Schneider et al. (59) who cloned the cDNA directly from MOLT-4 mRNA by using 
immune-selected polysomes. The murine TfR was cloned from myeloma cell mRNA 
and predicted an amino acid sequence sharing a high degree of homology with the 
human protein (60).
The availability of TfR cDNA has permitted probing of receptor message 
levels; hence, delineation of gene-level regulation for this system. The first such 
report, however, occurred prior to the cloning of TfR and utilized the in vitro 
translation of poly(A)* ENA and immunoprecipitation using polyclonal antibodies 
to infer the relative abundance of TfR transcripts (39). The iron chelator, 
desferrioxamine, was found to increase TfR message by 3-fold in K562 cells after 
an 8 hr incubation. Using pCDTR-1 as a probe, Rao et al. (61) confirmed by 
Northern blotting that desferrioxamine induced TfR mRNA and that hemin or 
diferric transferrin lowered receptor transcripts. Moreover, by crude nuclear run­
off assays, these changes appeared to result from transcriptional regulation.
The first demonstration that TfR message levels are altered during 
differentiation was shown using monocytes isolated from whole blood. When these 
cells were allowed to spontaneously mature to macrophages by culturing in vitro, 
TfR transcripts increased dramatically from undetectable levels in the freshly 
isolated monocytes (62). Biosynthetic regulation of TfR in a chemically-induced 
differentiation system was first reported by our laboratory. We showed that a 
decrease in the steady-state level of receptor transcripts correlates with and 
precedes a reduction in surface TfR in HL-60 cells induced along the granulocytic 
pathway by DMSO (63). A similar phenomenon was found subsequently when HL- 
60 cells were induced to differentiate by RA and ACM (64). While cells induced 
with TPA did not appear to invoke biosynthetic regulation to effect a characteristic
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rapid down-regulation of surface receptors, dramatic reductions in TfR transcripts 
apparently served to maintain low levels of receptor expression after 12 hours of 
treatment. Using nuclear run-off and transcript half-life studies, Trowbridge et al. 
(65) have subsequently demonstrated that the DMSO-induced decline in steady- 
state TfR mRNA levels is mediated at the transcriptional level. Nuclear run-off 
assays in the monocytic differentiation of HL-60 cells by dibutryl cyclic AMP 
revealed a decline in TfR transcription rates after 2 hours of inducer exposure (66).
It is already clear that TfR homeostasis is controlled at the gene level in 
a complex manner replete with inducing and suppressing elements. These include 
the intracellular iron concentration, the state of differentiation, and the phase of 
cellular growth. Molecular dissection of the TfR gene and mRNA have revealed 
multiple sites of positive and negative regulation. Kuhn et al. (67) first reported 
that the site of iron regulation appeared to be post-transcriptional, based on studies 
with transfected TfR cDNA’s possessing deletions in the 3’ untranslated region. 
It should be recalled that the original cloning of TfR cDNA identified a large 2.1 
kb untranslated segment of unknown function at the 3’ end of the message. This 
report postulates that an interaction between an iron-dependent factor and specific 
3’ sequences on the message may influence post-transcriptional events, such as 
processing of precursor mRNA, transport, or mRNA degradation. Recently, a 
trans-acting factor, which bound TfR mRNA and conferred iron-dependent 
regulation of TfR message stability, was identified using non-denaturing gel 
electrophoresis (68). Further characterization of the 3’ region of the TfR message 
identified the presence of five potential stem-loop structures as iron responsive 
elements similar to one found in the mRNA for human ferritin (69). When 
chimeric transcripts containing these iron responsive elements cloned into the 
human growth hormone gene were transfected into murine cells in transient
R eproduced with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
expression assays, the production of growth hormone became iron responsive. 
These 3’ elements on the TfR mRNA appeared to confer iron-regulated transcript 
stability, as the half-life of the message was 20-fold greater in the presence of 
desferrioxamine than under control conditions (70).
Conventionally, gene regulation is ascribed to the 5’ region of DNA, the site 
of regulatory protein binding to promoter or repressor elements. A 365 bp 
fragment from the 5’ upstream region of the TfR gene was isolated by Ruddle et 
al. (71). Sequence analysis revealed a TATA box, a consensus Spl recognition site, 
and a highly GC-rich region that consisted largely of four repeats of the sequence 
GGGGC, arranged as one inverted copy followed by 3 direct repeats. This motif 
was reminiscent of the promoter regions for the human dihydrofolate reductase and 
the murine interleukin 3 genes. This TfR promoter region also possessed iron- 
responsive properties. When a large 1.6 kb 5’ fragment of the TfR gene was 
subcloned upstream to the structural gene for chloramphenicol acetyltransferase, 
reporter gene mRNA levels were 3-fold higher when transfected cells were treated 
with desferrioxamine than after treament with hemin (72). Thus, TfR levels 
appear to be determined predominantly by the concentration of TfR message, with 
the regulatory regions for this gene composed of basal and inducible elements on 
both non-coding DNA sequences and untranslated mRNA. Such regulation has 
been intensively studied with the metallothionein gene, where the basal and 
inducible elements have been shown to operate in an independent fashion (73). 
Such regulation would presumably allow cells exquisite control over surface TfR 
activity, a function clearly critical to cellular metabolism, growth, and 
differentiation.
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Expression of the TfR is critical to maintain many critical cellular processes, 
including intracellular iron homeostasis, proliferation, and differentiation. 
Investigations of the regulatory components for this receptor system have yielded 
a wide assortment of potential mechanisms consistent with the role of TfR in a 
variety of pivotal cellular events. Transcription of the TfR gene may be modulated 
by protein:BNA interactions at various promoter sites. Message levels may further 
be altered by protein :RNA interactions at the 3’ untranslated region of the mRNA. 
Surface receptor levels may be affected by protein kinase C activity via 
phosphorylation and subsequent internalization of TfR. Finally, the receptor’s 
interaction with its ligand may be a function of its appropriate glycosylation during 
biosynthesis. The mechanism(s) which applies to the TfR modulation seen during 
the induction of leukemia cell differentiation requires precise definition. In 
addition, the delineation of etiological nature for this event may, perhaps, establish 
the true role of TfR activity during differentiation. Investigations of this nature 
require different tools than the commonly employed differentiation inducers which, 
in addition to modulating TfR expression, have a host of pleiotropic effects on cells. 
Antisense oligodeoxynucleotides may represent a suitable class of compounds with 
which to undertake these studies. By appropriate selection of target sequences, it 
is, in theory, possible to inhibit the expression of a single gene within a cell. Any 
such sequelae resulting from this could then be ascribed to the function of that 
single gene product.
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A ntisense RNA as H istorical P recursors to  A n tisen se  
Oligodeoxynucleotides.
The exploitation of synthetic DNA as a specific inhibitor of gene expression 
is relatively new. However, the concepts behind this approach was first proposed 
by Grineva et al. as early as 1967 (156,157). The pioneering work of Zamecnik 
and Stephenson (74,75) in 1978 first described the inhibition of Rous sacoma virus 
replication by oligonucleotides. In the following decade, this strategy was applied 
in a variety of viral and eukaryotic systems against many different cellular targets. 
In addition, the emergence of novel synthetic methods to modify the chemistry of 
oligonucleotides has permitted the continued development of more potent structural 
analogues of DNA. This field has only recently matured past the phenomenological 
stage to one in which critical investigations into the mechanism of antisense action 
within the cell are now being pursued. Recent studies of the pharmacokinetics and 
metabolism of oligonucleotides in in vivo models are, perhaps, harbingers of its 
potential role as a new class of chemotherapeutic agents. These exciting 
developments have been the topic of recent reviews (76,77,78,79).
The antisense DNA field can trace its roots to the discovery of RNA 
sequences which serve as endogenous biological inhibitors in prokaryotes and 
eukaryotes. This was first demonstrated for the osmoregulatory protein, OmpF, 
of E. coli (80). A novel species of RNA, termed micRNA (mRNA-interfering 
complementary RNA), was found to inhibit the translation of OmpF transcripts by 
hybridizing with it, resulting in premature termination of transcription of the 
OmpF gene or destabilization of OmpF mRNA. A eukaryotic analogue to micRNA, 
termed tcRNA102 (translational control RNA), was found to specifically inhibit 
translation of the chicken myosin heavy chain in vitro (81). Sequence analysis of
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this 102 bp molecule revealed segments complementary to the 5’ terminal part of 
the chicken myosin heavy chain mRNA.
This apparently endogenous strategy of gene regulation was pursued through 
the then newly developed methods of gene transfection into eukaryotic cells. 
Microinjection or calcium phosphate precipitation techniques permitted the 
introduction of foreign DNA into host cells where, after stable integration into the 
genome, expression of the gene product could be demonstrated. Rather than 
promoting the synthesis of a particular foreign protein, however, the expression of 
an endogenous gene could be inhibited if the transfected cDNA were inserted in 
a reversed orientation behind a promoter sequence. The antisense, rather than 
the sense, strand would then serve as a template for synthesis of an mRNA which 
would then be complementary to the coding transcript for the gene of interest. 
The RNA duplex thus formed would then hinder sense strand translation by 
mechanisms similar to those postulated for micRNA and tcRNA102.
This particular strategy, termed antisense RNA, was applied to a variety 
of eukaryotic targets. In 1984, Izant and Weintraub (82,83) constructed an 
antisense plasmid to the herpes simplex virus thymidine kinase (TK) gene behind 
either constituitive or inducible viral promoters. These were then co-microinjected 
with the normal sense herpes TK plasmid into TIC0 mouse L-cells and the induced 
TK activity was assessed by thymidine incorporation. Antisense transcripts 
complementary to as little as 52 bp of the TK gene inhibited thymidine 
incorporation, whereas the transfection of control plasmids were without effect. 
The sequence specificity of this process was shown by a lack of enzyme inhibition 
seen when the non-cross hybridizing chicken TK gene and the viral TK antisense 
construct were co-microinjected. In addition, suppression of endogenous actin gene 
activity by antisense RNA to actin was manifested by a reduction in actin
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microfilament cables by immunofluorescence and by a decreased growth rate. The 
authors concluded by stating that, "antisense RNA may be generally useful for 
suppressing the expression of specific genes in vivo and may be a potential 
molecular alternative to classical genetic analysis."
Indeed, the antisense RNA approach was quickly applied to one of the 
principle models of gene expression, fi-globin. Melton (84) showed RNA duplex 
formation and translational inhibition by pre-injecting antisense RNA into frog 
oocytes before the introduction of B-globin mRNA. Deletion mapping indicated 
that the aritisense molecules must hybridize to the 5’ end of the B-globin transcript 
in order to efficiently inhibit translation. The importance of antisense duplex 
formation at the 5’ end of targetted mRNA was also noted by Izant and Weintraub 
(83) in their studies of TK gene inhibition.
The rapid down-regulation of the c-myc oncogene is a well-described 
phenomenom seen during the chemically-induced differentiation of HL-60 cells (85). 
Although increased myc expression is generally seen in rapidly proliferating cells, 
gene transfer experiments have shown that the constituitive expression of c-myc 
inhibits the induction of differentiation in erythroleukemia cells (86,87). When HL- 
60 cells were stably transfected with an antisense construct to the myc oncogene, 
suppression of endogenous myc gene expression by antisense RNA, decreased cell 
proliferation, and the triggering of monocytic differentiation were seen (88). It was 
concluded that c-myc had a functional role in leukemia cell differentiation. 
However, like that of the transferrin receptor, the involvement of c-myc down- 
regulation in differentiation per se versus the cessation of proliferation which 
accompanies terminal differentiation is difficult to dissect.
Antisense RNA, while successful in vitro as a specific suppressor of gene 
activity, has inherent handicaps which may prevent its viability as a therapeutic
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modality. The delivery of large expression vector plasmids into mammalian cells 
requires laborious techniques such as calcium phosphate precipitation, 
microinjection, or electroporation. Since these methods are generally performed ex 
vivo on single cell suspensions, the number and types of cells amenable to these 
manipulations are severely limited. The incorporation of the DNA into the host 
genome cannot, a t present, be directed in a controlled manner. Without this 
capability, the possibility remains that the random integration of foreign DNA may 
disrupt functions of the host genome that lead to deleterious effects. Finally, it is 
difficult to control the level of expression of these plasmids once inside cells. 
Vector expression can be grossly modulated by employing inducible promoters, for 
example, the metallothionein promoter which responds to cadmium or the mouse 
mammary tumor virus promoter which responds to dexamethasone. However, the 
fine control over antisense RNA expression, already difficult to achieve in vitro, 
but presumably necessary for use in humans, is likely to be even more complex in 
an in vivo setting where host factors may interfere. All of these practical 
considerations served as stimuli for the development of synthetic 
oligodeoxynucleotides as antisense inhibitors of gene expression.
Phosphodiester Oligodeoxynucleotides as Antisense Inhibitors.
The advent of commercially available DNA synthesizers and improved 
methodologies for synthesizing DNA (reviewed in Ref. 89) ushered in 
oligodeoxynucleotides as viable alternatives to antisense RNA. As late as 1977, 
it was concluded that the synthesis of yeast alanine tRNA by conventional 
enzymatic and chemical means would require 20 man-years of effort (90). Today, 
DNA synthesizers can easily produce overnight an oligodeoxynudeotide 2 to 3 times 
the length of a tRNA molecule. Although there remains a daunting array of
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obstacles to overcome before these agents may be used therapeutically, 
oligodeoxynucleotides possess many attractive advantages as anti sense inhibitors.
Statistically, a sequence of 17 bp should be found only once in the entire 
human genome and considerably shorter sequences, i.e., 12-mers, may in principle 
be used to target mRNA since only the transcribed fraction of DNA must be 
considered. The production of these short sequences by conventional. DNA 
synthesizers is trivial, although synthesis of pharmaceutical amounts of purified 
DNA remains economically unfeasible. Furthermore, short sequences, as opposed 
to multi-kilobase long plasmids, easily enter cells without the need for 
extracorporeal manipulations, such as microinjection. The synthesis of these 
compounds by automated means permits virtually any gene, whose sequence is 
known, to be targetted. Lastly, newly developed synthetic analogues which may 
increase the potency or efficacy of antisense molecules may be rapidly assessed in 
in vitro systems.
The innovative studies by Zamecnik and Stephenson (74,75) of antisense 
oligodeoxynucleotides in mammalian cell transformation by Rous sarcoma virus 
(RSV) were the earliest demonstrations of sequence specific inhibition by synthetic 
DNA. A tridecamer (13-mer) complementary to terminal repeat sequences of viral 
35S RNA was found to inhibit viral replication in chick embryo fibroblast cultures 
infected with RSV. This was assessed by measuring reverse transcriptase activity 
released into the culture medium by infected cells. Moreover, in cell-free 
translation systems, it was determined that this tridecamer inhibited the 
translation of viral RNA in a sequence and concentration dependent manner.
The early work in this field by Zamecnick and others established some of 
the basic tenets of antisense oligodeoxynucleotides as potential therapeutic agents. 
Ideally, these compounds must fulfill criteria concerning selectivity of action,
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molecular stability, and solubility. Obviously, in order to minimize toxicity, any 
chemotherapeutic agent must specifically interact with its target site. 
Oligodeoxynucleotides interact with target DNA or RNA by Watson-Crick base 
pairing rules. Hence, subtle alterations to the linear base sequence of antisense 
molecules should, in theory, dramatically affect their hybridization potential and, 
therefore, their biological efficacy. Since a variety of nucleases, which exist 
intracellularly and in sera, can degrade oligodeoxynucleotides, antisense molecules 
must be sufficiently stable to enzymatic hydrolysis in order to reach their targets 
at effective concentrations. Finally, these compounds must be water-soluble, yet 
be able to pass through the cell membrane. The polyanionic character of normal 
phosphodiester oligodeoxynucleotides may impede transport through the cell 
membrane. Conversely, a compound that is too lipophilic may have limited 
practical potential because of its reduced aqueous solubility. As will be discussed 
later, recent synthetic modifications to the basic chemistry of DNA structure have 
permitted the development of analogues which have improved the ability of 
oligonucleotides to better satisfy the above criteria.
The early studies with antisense DNA were limited to first generation 
oligodeoxynucleotides with intemucleoside phosphodiester linkages similar to that 
of native DNA. The HL-60 cell line has served as a convenient model system for 
many of the early antisense studies. Wickstrom et al. (91) employed a 
pentadecamer (15-mer) complementary to the initiation codon region of the c-myc 
oncogene. When HL-60 cells were incubated with oligodeoxynucleotides at 10 uM, 
a reduction in myc protein was observed by immunofluorescence and by 
radioimmunoprecipitation. Furthermore, cell proliferation was inhibited in a dose- 
dependent manner. Experiments using antisense pentadecamers to the vesicular 
stomatitis virus (VSV) or to the human immunodeficiency virus (HIV) tat gene as
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negative controls were without effect. Using the same system, Holt et al. (92) 
demonstrated similar results, hut, in addition, found that the anti-myc 
oligodeoxynucleotide weakly induced granulocytic differentiation. Maturation was 
assessed by morphology and NBT staining, with approximately 30% of cells 
evidencing NBT positivity after 3 days of treatment. These results, however, 
contrasted with the previously described studies of antisense RNA to myc which 
resulted in monocytic differentiation (88).
To further address the role of c-myc protein function, the same anti-myc 
pentadecamer was used to study the mitogen-induced activation of lymphocytes. 
The c-myc gene is normally silent in resting lymphocytes, but is activated upon 
mitogen stimulation. Both c-myc protein expression, quantitated by Western 
blotting and immunoprecipitation, and entry into S phase, assessed by propidium 
iodide staining, were completely inhibited by 30 uM of antisense DNA in PHA- 
stimulated lymphocytes (93). An antisense molecule to VSV was without effect. 
Interestingly, the anti-myc oligodeoxynucleotide did not prevent the induction of 
TfR, interleukin 2 receptors, and sH-uridine incorporation into mitogen-stimulated 
cells. Since these phenomena are part of the G0 to G, transition following 
lymphocyte activation, c-myc expression appeared critical for S phase entry or 
traversal. However, TfR and interleukin 2 receptor expression were apparently 
insufficient to support DNA synthesis in the absence of normally induced levels of 
c-myc protein. These results were verified for interleukin 2 stimulation of T 
lymphocytes (94).
Antisense inhibition by phosphodiester oligodeoxynucleotides has been 
demonstrated for a variety of other eukaryotic proteins. An octadecamer (18-mer) 
to the c-myb oncogene interfered with the normal hematopoiesis of human bone 
marrow mononuclear cells at a concentration of 14 uM (95). This same molecule
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displayed sequence-specific growth inhibition of human myeloid leukemia cell lines, 
including HL-60, however, no differentiative effects were noted (96). Finally, the 
anti-myft DNA acted similarly to the anti-myc oligomer in preventing S phase entry 
in the mitogen-stimulated lymphocyte model (97). DNA synthesis and mitosis were 
suppressed in exponentially growing Balb/c3T3 cells exposed to 30 uM of antisense 
oligodeoxynucleotides to cyclin, otherwise known as the proliferating cell nuclear 
antigen (98). Antisense DNA against the dihydrofolate reductase gene caused 
specific translational arrest in a rabbit reticulocyte lysate system (99). 
Oligodeoxynucleotide Analogues as Antisense Inhibitors.
Although the normal phosphodiester oligodeoxynucleotides have been used 
with success as antisense inhibitors in tissue culture systems, their inherent 
susceptibility to enzymatic hydrolysis by nucleases severely limits their utility in 
vivo and, sometimes, in vitro. This is a rapid process. In HeLa cell 
postmitochondrial cytoplasmic extracts, a half-life of 30 min was observed for 
oligodeoxynucleotide degradation (100). In undiluted bovine calf serum, degradation 
of the 5* end-labelled DNA appeared complete within 15 min. These data may be 
overestimates since a delineation was not made between intemucleoside bond 
hydrolysis and 59 phosphatase removal of the radiolabel in these studies.
In addition, the polyanionic character of the phosphodiester bonds may 
impede passage of antisense molecules through cell membranes. Theoretically, a 
reduction in the charge density of the intemucleoside bonds may improve cellular 
deliver of antisense molecules. For these reasons, and to improve efficacy, 
attempts have been made to structurally modify synthetic DNA without 
significantly affecting the hybridization potential. Most attention has focused on 
the intemucleoside linkages, although the base and ribose moieties are also 
potential sites for modification (Fig. 2a).
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Figure 2 a. Intemucleoside chemistry of synthetic oligonucleotides. A 
representative intemucleoside bond in a synthetic oligonucleotide is shown. Base 
is adenine, guanine, cytosine, or thymidine. Substituents to the intemucleoside 
phosphate may appear at the X  and Y  positions, with both occupied by oxygen 
atoms in normal, unmodified oligonucleotides. The common terminology for the 
variously substituted DNA analogues are shown.
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The methylphosphonates were among the first candidate DNA analogues 
investigated. Miller and Ts’o (101) first developed these nonionic nucleic acid 
analogues which contain a 3’-5’ methylphosphonate group in place of the negatively 
charged phosphodiester group. These compounds were shown to be resistant to 
nuclease hydrolysis and to penetrate mammalian cells in culture (102). Although 
these analogues have been vigorously pursued as anti-viral agents in a variety of 
systems, they suffer from their own inherent disadvantages which may preclude 
their eventual utility. The synthesis of methylphosphonates is not stereospecific, 
therefore, a chiral center will be generated about each methylphosphonate linkage. 
An oligomer of base length n will have 2(n'1) diastereoisomers. It is unknown if 
correct hybridization with mRNA is abrogated by chirality at the intemucleoside 
bond. They are relatively insoluble in aqueous media; in fact, methylphosphonates 
without polar terminal phosphate or phosphodiester groups and longer than 12- 
mers are virtually insoluble (103). Because of this enhanced lipophilicity, these 
molecules may selectively partition within cellular membrane structures, thereby 
limiting their free concentration. All of these factors may contribute to the 
necessity of using high concentrations (typically 100-300 uM) in order to achieve 
appreciable antisense activity.
A second class of oligodeoxynucleotide analogues are the phosphorothioates. 
Here, one of the nonbridging oxygen atoms in each intemucleoside phosphate 
linkage is replaced by a sulfur atom, thus providing several theoretical advantages. 
This reduces the anionic charge density at each intemucleoside bond and, 
therefore, of the entire molecule; hence, cellular uptake may be improved. These 
compounds retain aqueous solubility since this substitution does not confer the 
extreme lipophilicity seen with the methylphosphonates. This substitution also 
provides resistance to enzymatic hydrolysis as the phosphorothioate linkage is not
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a good substrate for serum and cellular nucleases. Finally, the synthesis of these 
analogues from deoxynucleoside hydrogen phosphonate precursors is relatively 
simple and easily adapted to conventional automated synthesizers (104). like  the 
methylphosphonates, however, phosphorothioates contain chiral phosphorus centers 
which create multiple diastereomers.
The actual physicochemical properties of the phosphorothioate 
oligodeoxynucleotides have been meticulously investigated by Stein et al. (105). 
The nuclease susceptibility of these compounds was tested against a variety of 
DNases. By comparing oligomer half-lives during digestion, phosphorothioate 
analogues were found to be approximately 20-fold more stable to the endonuclease 
Sj and to the exo- and endonuclease Pi than their phosphodiester counterparts. 
Against snake venom phosphodiesterase, the phosphorothioates were virtually 
invulnerable with half-lives over 1000 times greater than the corresponding 
phosphodiesters. As will be discussed below, one potential mechanism for antisense 
DNA activity is hybridization to mRNA, thereby creating a mixed RNA:DNA 
hybrid. This complex serves as a substrate for RNase H which cleaves only the 
RNA strand of the heteroduplex; hence, the mRNA target of an antisense molecule 
will be selectively hydrolyzed. In these studies, duplexes consisting of a 
homopolymer of deoxythymidine hybridized to oligoadenylic acid were digested with 
RNase H. This reaction occurred approximately 20 times faster with a 
phosphorothioate homopolymer than with a phosphodiester homopolymer.
That RNase H activity is greater with the phosphorothioates may underlie 
their enhanced biological efficacy over the conventional phosphodiester oligomers. 
In a direct comparison of antisense activity, normal phosphodiester 
oligodeoxynucleotides were compared with their corresponding analogues in the 
phosphorothioate, methylphosphonate, and phosphotriester series (106). Similar
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sequences, directed against the initiation codon region of the chloramphenicol 
acetyl transferase gene (CAT), were tested for their ability to inhibit the expression 
of plasmid-directed CAT activity in CV-I cells. At 30 uM, the phosphorothioate 
analogues were most efficacious, followed by the methylphosphonate and triester 
analogues; the least activity was shown by the normal phosphodiester compounds. 
This was evident despite the fact that the hybridization potential, as reflected by 
duplex melting temperatures, for the phosphorothioates are reduced by 15-20°C 
relative to the corresponding phosphodiester sequences (105). Thus, although 
phosphorothioates do not form heteroduplexes with mRNA as readily as their 
phosphodiester counterparts, they may be more biologically active as antisense 
molecules due to their resistance to DNase degradation and their promotion of 
RNase H scission activity.
Although a variety of other synthetic analogues exist, these have been 
applied to fewer biological systems. These include modifications of the 
intemucleoside linkages to create phosphorami date, phosphotriester, or 
phosphorodithioate groups. The recently described phosphorodithioates have all of 
the previously mentioned advantages of the phosphorthioates. However, the fact 
that both nonbridging oxygen atoms of the intemucleoside bonds have been 
replaced by sulfur results in retention of achirality about the phosphorus atom. 
The theoretical problems imposed by the 2<n l) diastereoisomers formed, therefore, 
would be eliminated.
Another class of oligodeoxynucleotides are the a-analogues in which the B- 
anomeric linkage formed by the dexoyribose moiety with the purine or pyrimidine 
base in native DNA is transposed into the unnatural a  linkage. This modification 
renders these molecules nuclease resistant. Interestingly, the a-analogues form 
parallel rather than antiparallel duplexes with native J3-DNA or RNA.
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Unfortunately, duplexes formed by a-DNA:mRNA hybridization are poor substrates 
for RNase H (107). In addition, cost is a significant problem at present for these 
compounds; cc-anomeric nucleoside precursors cost as much as 30 times that of 
their £ counterparts (103). Lastly, oligodeoxynucleotides may be modified by the 
covalent attachment of conjugates to increase their biological activity. Nucleic acid 
intercalators, such as acridine, may be conjuated to oligomers to stabilize 
hybridization interactions with DNA or RNA (108,109). The conjugation of an iron- 
EDTA group provides cleavage activity to oligomer in the form of reactive oxygen 
radicals generated in the vicinity of the duplex (110). The attachment of a 1,10- 
o-phenanthroline copper group to oligomers also imparts cleavage activity by 
similar mechanisms (111). The oxygen radicals generated are so potent, however, 
that these compounds are degraded by autocatalysis.
Antisense DNA Analogues as Antiviral Agents.
While conventional phosphodiester oligomers have been exploited extensively 
to suppress oncogene expression in eukaryotic cells, the antisense analogue 
compounds have proven to be extremely active as inhibitors of viral replication, 
especially that of the human immunodeficiency virus (HIV). Eight years after 
publishing their landmark studies on the suppression of RSV replication (74,75), 
Zamecnik and coworkers (112) investigated the ability of unmodified phosphodiester 
antisense oligodeoxynucleotides to inhibit HIV. At 50 uM, a 20-mer complementary 
to the HIV splice acceptor site inhibited viral replication, as assessed by reverse 
transcriptase activity, and gene expression, as determined by the production of 
virus-encoded pl5 and p24 proteins. Additional antisense oligomers targetted to 
other regions of the viral genome proved less inhibitory in these assays. In 
expanded studies, this group showed that antisense 20-mers against the cap site,
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5’ untranslated region, and poly(A) signal of HIV RNA were most effective at 
inhibiting syncitia formation and p24 elaboration in virally infected cells (113). 
These sequences are related geographically and are found within the repeated 
sequence at the ends of retroviral RNA.
The methylphosphonate analogues were initially assessed in non-HIV viral 
systems. Miller and Ts’o (114) reported that a methylphosphonate octamer against 
the splice acceptor site of herpes simplex virus (HSV) type 1 showed antiviral 
activity by a variety of measures, including actual virus titers and viral DNA and 
protein synthesis. When a vesicular stomatitis virus model was tested, the same 
group determined that these analogues specifically inhibited viral protein synthesis 
in an in vitro translation system and viral replication during the infection of mouse 
cells (115). Unfortunately, due to the aforementioned disadvantages with these 
analogues, the concentrations of oligomers used in these experiments was high 
(100-300 uM). Zamecnik’s group (116) showed that these analogues, at only 20 
uM, could be exploited to inhibit HIV. The reason(s) for the striking difference 
in the effective concentrations between this and the previous studies was not 
addressed.
By far, the phosphorothioate analogues have proven to be the most 
intriguing and efficacious anti-HIV oligomers. A number of interesting observations 
were reported by Matsukura et al. (117) in the first investigation of 
phosphorothioates in the HIV system. First, phosphorothioate inhibition of HIV 
activity was dependent on length, with 28-mers being more potent than 14-mers; 
5-mers showed no activity. Surprisingly, the antiviral activity of these compounds 
was not sequence-specific. In fact, the most potent antiviral activity was shown 
by a 28-mer phosphorothioate oligodeoxycytidine homooligomer (S-dCas) rather than 
antisense molecules complementary to HIV sequences. The antisense
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phosphorothioates were active, but at higher concentrations (10-25 uM). As little 
as 5 uM of S-dCjg completely inhibited the cytopathic effect of HIV on de novo 
infected T-cells without being cytotoxic for non-infected cells. Furthermore, while 
S-dCM inhibited the de novo synthesis of HIV DNA in newly infected cells down 
to 1 uM, it failed to inhibit gag protein synthesis in chronically infected cells at 
concentrations up to 25 uM. This suggested that the phosphorothioate analogues 
may be effective antiviral agents by mechanisms independent of antisense means. 
The authors concluded that the antiviral activity of S-dC^ was mediated by 
inhibition of HIV proviral DNA synthesis, possibly by direct interference with the 
retroviral reverse transcriptase. This scheme, involving direct interference of a 
DNA modifying enzyme by the phosphorothioate homooligomer, was supported by 
work from another group showing that S-dCjg was a competitive inhibitor of the 
HSV type 2 DNA polymerase, but interfered with human DNA polymerases less 
effectively (118).
Sequence-specific antisense suppression of HIV expression by 
phosphorothioates was eventually demonstrated by Matsukura et al. (119) in a 
follow-up report. A phosphorothioate 28-mer (S-arev), complementary to the 
initiation sequence of HIV-1 rev, selectively inhibited the expression of a retroviral 
protein, p24 gag, in T-cells chronically infected by HIV. This process was dose- 
dependent through 25 uM of S-ocrev, which inhibited viral protein production by 
90% without significant toxicity. Antiviral activity was also assessed by Northern 
blotting; S-arev treatment of infected cells resulted in a disappearance of the 9.2 
kb genomic mRNA of HIV. The sequence specificity of this inhibition was shown 
when equivalent doses of S-dC^, an unmodified phosphodiester antisense oligomer 
to rev, and a random sequence phosphorothioate molecule with the same base 
composition as S-arev proved ineffectual. The increased activity against HIV by
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the phosphorothioate analogues over identical sequences in the normal 
phosphodiester series was confirmed independently (120). Furthermore, viral 
inhibition by these antisense compounds was not a universal phenomenon as a 
phosphorothioate antisense oligomer to the HIV gag gene did not alter the mRNA 
profile of viral expression. Taken together, these data suggest that 
phosphorothioate oligodeoxynucleotides may exert antiviral effects by two distinct 
mechanisms. The homooligomers, i.e., S-dCjg, may selectively inhibit the function 
of retroviral reverse transcriptase, while antisense molecules, i.e., S -a re v , may act 
more classically to promote translation arrest of targetted viral mRNA. These 
targets, however, must be appropriately selected as implied by the experiments 
with the anti-gag oligomer.
M echanisms of Antisense Oligodeoxynucleotide Inhibition of Gene Activity.
Only recently has the molecular mechanism(s) of antisense activity been 
systematically investigated. Conventionally, there are two postulated mechanisms 
by which antisense oligomers may induce hybridization arrest of translation (Fig. 
2b). The formation of an RNArDNA duplex may exert a direct steric effect, 
blocking the binding of factors required for the initiation of translation or impeding 
translocation of the ribosome along the mRNA resulting in chain termination. 
Alternatively, the mRNA may be cleaved by RNase H at the site of the RNA:DNA 
heteroduplex. RNase H, a ubiquitous enzyme required for DNA replication, is 
thought to digest the short RNA primers used to initiate DNA synthesis. Walder 
and Walder (121) have shown that in freshly preparated reticulocyte lysates, which 
contain only 1-2% of the level of RNase H in nucleated cells, nearly 100% of 
targetted mouse a- or B-globin mRNAs were digested at the site of hybridization 
with a complementary phosphodiester oligodeoxynucleotide within 1 hour under
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Figure 2 b. Potential mechanisms for antisense mediated gene inhibition. 
Above. The typical pathway of protein synthesis is shown. DNA is transcribed 
into mRNA containing a poly-A4 tail onto which ribosomes bind thereby initiating 
the synthesis of the encoded protein.
Middle. The hybridization of a complementary antisense oligonucleotide to its 
target sequence on single-stranded mRNA can mediate inhibition of gene expression 
through one of two mechanisms. In hybridization arrest, the resultant DNA:RNA 
heteroduplex prevents the binding of elements involved in protein synthesis. These 
may include, but are not limited to, the ribosomes. Alternatively, this DNA:RNA 
heteroduplex is a substrate for RNase H which specifically digests the RNA strand. 
The truncated mRNA does not serve as a normal substrate for the binding of the 
protein synthetic machinery.
Bottom. The hybridization of a synthetic oligonucleotide to double-stranded DNA 
results in the formation of a DNA triplex. This structure may prevent the 
recognition or binding of transcriptional elements thereby inhibiting gene 
expression.
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conditions of active translation. Poly(rA)*oligo(dT), a competitive inhibitor of 
RNase H, abolished the translational inhibition effected by the antisense oligomers. 
This indicated that the formation of a RNA:DNA heteroduplex alone was 
insufficient to inhibit protein synthesis; cleavage of the mRNA by RNase H is 
requisite to achieve translational arrest.
An unconventional, yet potentially exciting, mechanism of antisense gene 
inhibition involves targetting duplex DNA rather than single-stranded mRNA. This 
idea has conceptual advantages and disadvantages compared to the conventional 
approaches described above. Whereas multiple copies of antisense 
oligodeoxynucleotides would be required intracellularly to hybridize to the numerous 
copies of mRNA, which are themselves turning over constantly, theoretically, only 
one antisense molecule is necessary to inhibit gene expression at the DNA level. 
A potential limitation to this approach, oligomer transport through the complex 
nuclear membrane to the chromosomes, has been recently demonstrated. The 
primary drawback is that, unlike duplex formation where the well-characterized 
Watson-Crick base pairing scheme applies, our understanding of the 
physicochemical rules for triplex formation is extremely limited and controversial. 
Using oligodeoxynucleotides, one report provided NMR evidence of triplex DNA in 
which one homopurine and one homopyrimidine strand are Watson-Crick base 
paired, and another homopyrimidine strand is Hoogsteen base paired parallel to 
the purine strand along the major groove (122). Others have evidence for a 
purine-rich oligomer binding in a parallel orientation along the major groove to the 
purine-rich strand of a double helix (123).
In spite of these difficulties, antisense inhibition by putative triplex DNA 
formation has been demonstrated in two systems. Cooney et al. (123) first 
synthesized a purine-rich 27-mer designed to bind duplex DNA at a single site
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within the 5’ end of the human c-myc gene, 115 bp upstream from the origin of 
transcription. This oligomer inhibited c-myc transcription in vitro and was found 
to form a DNA triplex, as assessed by gel mobility shift and DNase footprinting 
assays. Maher and co-workers (124) described a pyrimidine-rich 
oligodeoxynucleotide which blocked the recognition of a double helical 
metallothionein promoter by various DNA binding proteins. The inhibition of 
binding by the prokaryotic modifying enzymes, Ava I restriction endonuclease and 
Taq I methylase, and by the eukaryotic transcriptional factor, Spl, to the 
homopurine target site was sequence-specific.
The development of oligodeoxynucleotides as antisense molecules represents 
a logical extension of the original discoveries of endogenous RNA molecules as 
regulators of gene expression in prokaryotes and eukaryotes. The advent of 
commercially available DNA synthesizers and simplified chemical methodologies for 
DNA production was a crucial catalyst in accelerating the progress of this field. 
Where oligodeoxynucleotides were once oddities limited to synthetic chemists, these 
technologies have provided abundant supplies of a nearly infinite selection of 
antisense sequences to cell and molecular biologists for the study of and 
intervention of gene expression. In less than a decade, second generation 
analogues which address many of the inherent limitations of the native 
phosphodiester series have been developed and confirmed to be more efficacious. 
Although experience with these compounds has been, for the most part, limited to 
in vitro settings, antisense oligodeoxynucleotides are currently being investigated 
in animal models for their pharmacokinetics and metabolism in vivo. With the 
potential of clinical trials on the horizon, the application of antisense 
oligodeoxynucleotides and their analogues as specific inhibitors of gene expression
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in the treatment of disease is distinctly possible. The continued study of these 
compounds in a variety of systems may expedite that possibility.
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MATERIALS AND METHODS
Chemicals and Cells.
DMSO, TPA, RA, NBT, a-naphthyl acetate, aprotinin, insulin-transferrin- 
selenium, bovine serum albumin, gentamycin, penicillin/streptomycin, propidium 
iodide, ribonuclease type I-A, dibutyl phthalate, dinonyl phthalate, and pre-stained 
protein molecular weight markers were purchased from Sigma Chemical Co. (St. 
Louis, MO). SB (#21,329-2), carbon disulfide (#27,0660-0), pyridine (#27,097-0), and 
triethylamine (#23,962-3) were obtained from Aldrich Chemicals (Milwaukee, WI). 
ACM was a gift from Bristol-Myers Co. (Wallingford, CT). FITC-conjugated and 
unconjugated anti-human transferrin receptor monoclonal antibody was purchased 
from Becton-Bickenson Inc. (Mountain View, CA). Paraformaldehyde and XRP-5 
X-Omat film were supplied by Eastman Kodak Co. (Rochester, NY). Nonidet P- 
40 was obtained from US Biochemical Corp. (Cleveland, OH). Guanidinium 
thiocyanate was purchased from Fluka Chemical Corp. (Hauppauge, NY). 
Oligonucleotide sizing markers were obtained from Pharmacia LKB (Piscataway, 
NJ). Enzymobead radioiodination reagent and 96-well dot blot manifold were 
supplied by Bio-rad Laboratories (Richmond, CA). Na125I (carrier-free, 3.7 GBq/ml) 
and Rainbow molecular weight markers were supplied by Amersham (Arlington 
Heights, IL). {^PjdCTP (>3000 Ci/mmol), l^Pjgamma-ATP (>3000 Ci/mmol), 
[“SJmethionine (>800 Ci/mmol), En*Hance, and Gene Screen hybridization filters 
were purchased from New England Nuclear Corp. (Boston, MA). Human HL-60 
promyelocytic leukemia cells, a gift of Dr. Robert C. Gallo of the National Cancer 
Institute, were passaged in RPMI 1640 culture medium (Grand Island Biological 
Co., Grand Island, NY) supplemented with 15% fetal bovine serum (Grand Island 
Biological Co.) and penicillin/streptomycin (Grand Island Biological Co.) in a
42
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humidified atmosphere of 95% air/5% C02. In some experiments, a sub-clone of 
HL-60 cells adapted to growth in serum-free culture medium was employed. These 
cells, a gift of Dr. Eric Wickstrom of the University of South Florida, were 
passaged in RPMI 1640 supplemented with 1 ml/1 insulin-transferrin-selenium, 0.4 
g/1 bovine serum albumin, gentamycin, and penicillin/streptomycin.
Cellular Proliferation and Differentiation.
HL-60 cells were resuspended in fresh growth medium at 1 to 2 x 10s 
cells/ml in the presence of vehicle or an inducer of differentiation at the indicated 
concentrations. At daily intervals thereafter, cell numbers were determined using 
a Coulter Model ZBM particle counter (Coulter Electronics, Hialeah, FL). 
Granulocytic differentiation was assessed by NBT reduction (13) and monocytic 
differentiation by non-specific esterase staining, using a-naphthyl acetate as a 
substrate (125). For antisense oligodeoxynucleotide experiments, cells were 
resuspended at 0.5 to 1 x IQ5 cells/ml and grown for 24 hr before the addition of 
antisense DNA.
DNA Histograms.
At indicated intervals, 106 cells were fixed in 70% ethanol and stored at 4°C 
for up to 1 week. Following RNase treatment, 30,000 cells were stained with 
propidium iodide (0.05 mg/ml) as described by Crissman et al. (126). Briefly, 10s 
cells were pelleted, washed once with cold PBS, three times with cold 95% EtOH, 
incubated at 37°C for 30 min in 1 mg/ml ribonuclease type I-A in PBS, and stained 
with 0.05 mg/ml propidium iodide in PBS for 30 min at 4*0. Histograms of 
relative cellular DNA content were obtained on a Becton-Dickenson FACS IV flow 
cytometer.
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Im munofluorescence of Surface T ransferrin  Receptor.
At indicated intervals, IQ6 cells were removed, washed free of experimental 
medium and incubated with or without FITC-conjugated monoclonal anti-human 
transferrin receptor antibody at a 1:5 dilution in ice-cold culture medium for 30 
min at 4°C. Cells were then washed twice with 1 ml of PBS at 4°C and fixed with 
2% paraformaldehyde in PBS at 4°C. Cell-associated fluorescence was detected 
using a Becton Dickenson FACS IV flow cytometer. Relative amounts of cell 
surface receptor were quantitated by calculating the linear difference in 
fluorescence intensities between cells exposed and not exposed to the antibody.
U5I-Transferrin Binding.
Radioligand binding to cell surface receptors was assessed according to the 
method of Ishiguro (personal communication). Human Tf, saturated with iron 
using FeCynitrilotriacetic acid at a ratio of 1:2, was purified through a Sephadex 
G-25 column equilibrated with 0.1 M NaC10« by the method of Bates and 
Schlabach (127). Full saturation of Tf with iron was ascertained by an A^A^o 
ratio of 0.045. The concentration of diferric Tf was determined spectroscopically 
using an A ^  (1%) value of 14.0, and a molecular weight of 80 kD for Tf (128). 
Diferric Tf (500 ug) was radioiodinated with 1 mCi Nat25I by the solid-phase 
lactoperoxidase and glucose oxidase method and purified through a Bio-gel P-6DG 
column, according to the procedure provided by the manufacturer. Specific 
activities of 126l-Tf ranged from 1,100 to 2,300 cpm/ng. HL-60 cells at a density of 
1.3 x 107 cells/ml were incubated with ,26I-Tf in binding buffer (0.13 M NaCl, 5 mM 
KC1, 2 mM MgClj, 25 mM HEPES (pH 7.4), 0.1% glucose, 5 mg/ml of bovine serum 
albumin) for 1 hr on ice. Duplicate or triplicate 100 ul aliquots were layered onto 
300 ul of a mixture of dibutyl phthalate and dinonyl phthalate (75.3:24.7, v/v) and
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cells were pelleted through the oil by a 15 sec centrifugation in an Eppendorf 
microfuge (129). Aqueous and oil layers were aspirated and the tips of the tubes 
containing the cell pellets were cut off. Radioactivity was determined using an 
LKB-Wallac Compugamma counter. The radioactivity found in the presence of 
excess unlabelel Tf (1 mg/ml) was considered nonspecific and was subtracted from 
the values obtained in the absence of unlabeled ligand (total binding) to obtain 
specific binding.
Im m unoprecipitation of Metabolically Labeled TfR.
Cells were washed twice with methionine-free RPMI 1640 medium 
containing 15% fetal bovine serum, suspended into the methionine-free medium at 
a  density of 1.5 x 107 cells/ml and labeled with [“SJmethionine at a concentration 
of 0.5 mCi/ml for the indicated intervals. For pulse-chase studies to determine 
cellular TfR t1/2, cells were washed twice with normal growth medium and 
resuspended at the initial cell densities in methionine-containing RPMI 1640 with 
15% fetal bovine serum for varying periods of time. Labeled cells were washed 
twice with PBS and lysed in an extraction buffer (50 mM Tris-HCl (pH 7.4), 150 
mM NaCl, 5 mM EDTA, 0.5% Nonidet P-40, 0.2 mM PMSF, 5 ug/ml aprotinin) at 
a density of 1.5 x 107 cells/ml at 4°C for 5 min. Lysates were clarified by 
centrifugation at 12,000 x g at 4°C for 5 min. Total incorporation of the labeled 
amino acid into proteins was monitored by precipitating macromolecules onto GF/C 
filters (Whatman, Clifton, NJ) with 25% trichloroacetic acid and 2% casamino acids 
following brief base hydrolysis with 1 N NaOH and 1.5% H20 2. Labeled TfRs were 
isolated by immunoprecipitation using 10 to 15 ul of a monoclonal anti-human TfR 
antibody at 4°C for 2 hr. The immunocomplex was precipitated by 30 ul of 
Protein-A-agarose (Pierce, Rockford, IL) at 4°C for an additional hour. The
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immunoprecipitate was pelleted by centrifugation for 30 8 at 12,000 x g and 
washed 4 to 5 times with 1 ml of the extraction buffer. Finally, the 
immunoprecipitate was boiled in sample buffer (0.1 M Tris-HCl (pH 6.8), 20% 
glycerol, 2% SDS, 2% B-mercaptoethanol, 0.05% bromophenol blue) and analyzed 
by SDS-PAGE by the Laemmli method (130) using a 5% stacking gel and a 7.5% 
running gel. Following electrophoresis, the gels were fixed in 30% methanol and 
10% acetic acid twice for 30 min. The gels were processed for fluorography by 
impregnation with En3Hance for 30 min followed by precipitation with cold water 
for 30 min. Dried gels were exposed to XKP-5 X-Omat film for autoradiography.
M easurem ent of T ransferrin  Receptor Specific mRNA.
At indicated intervals, total cellular RNA was extracted by a modification 
of the guanidinium thiocyanate method of Chirwin et al. (131) as described 
previously (63). Samples were evaluated, by dot blot or northern blot analyses. 
For dot blots, aliquots of RNA (20 ug and successive 1:2 dilutions) were applied to 
Gene Screen films via a 96-well manifold. For northern blots, 10 ug of RNA 
samples were subjected to electrophoresis in 1.2% agarose/formaldehyde gels and 
then transferred to Gene Screen using 5 x SSC (1 x SSC is 0.15 M NaCl plus 
0.015 M sodium citrate). Samples were cross-linked to filters by brief UV 
irradiation (132). Pre-hybridization was performed for 16 to 24 hrs at 42°C in a 
solution containing 50% deionized form amide, 10% dextran sulfate, 1% SDS, 0.2% 
bovine serum albumin, 0.2% polyvinylpyrrolidone, 0.2% Ficoll, 0.1% sodium 
pyrophosphate, and 1 M NaCl in 50 mM Tris-HCl (pH 7.5) with 100 ug/ml of 
denatured salmon sperm DNA. Hybridization reactions were conducted for 20 to 
24 hrs in the same buffer at 42°C with 50 ng of a BamHl fragment from the 
human TfR cDNA probe pcD-TRl (57) oligolabeled with [32P]dCTP by the method
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of Vogelstein (133). Alternatively, a cDNA probe for fi-actin, pAl (134), was 
employed alone or hybridized simultaneously with the TfR cDNA probe. Filters 
were washed with 2x SSC plus 0.5% SDS for 15 min at 25°C, 0.2 x  SSC plus 0.2% 
SDS for 20 min at 42°C, and 0.1 x SSC plus 0.5% SDS for 30 to 60 min at 60°C. 
Dried filters were exposed to XRP-5 X-Omat film with an intensifying screen. 
Developed films were analyzed by digital densitometry.
Synthesis and  Purification of Phosphodiester Oligodeoxynucleotides.
Conventional phosphodiester oligodeoxynucleotides were synthesized using 
standard solid phase phosphoramidite chemistry on an Applied Biosystems Model 
380B DNA Synthesizer. After manual deprotection with concentrated NH4QH at 
55°C overnight, the oligodeoxynucleotides were resuspended in distilled water and 
subject to reverse phase liquid chromatography or HPLC purification. De-salting 
was accomplished by a modification of the method of Lo et al. (135). Briefly, one- 
half of the yield from a 1 micromole synthesis was resuspended into 100 ul of 
distilled water and loaded onto a Sep-Pak cartridge (Waters Associates, Milford, 
MA) previously equilibrated with 10 ml of acetonitrile followed by 10 ml of 10 mM 
NH4QH. The cartridges were flushed with 10 ml of 10 mM NH4QH followed by 
5 ml of air. The oligodeoxynucleotides were eluted with 3 ml of 20% acetonitrile 
in distilled water with the majority of the sample being eluted within the first 1.5 
ml. The eluate was evaporated to dryness in a Speed-Vac (Savant Instruments, 
Farmingdale, NY) with concomitant application of heat. Alternatively, equal 
amounts of oligonucleotides were purified by HPLC using a Vydac C4 reverse phase 
column (25 cm x 4.6 mm, 330-Angstrom pore size) (Separations Group, Hesperia, 
CA). The HPLC buffer system consisted of: A= 100 mM triethylammonium
acetate (TEAC) and B= 100 mM TEAC + 50% acetonitrile. Separation was
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achieved at a flow rate of 1 ml/min using a linear gradient from 0% to 50% "B" 
over 40 minutes, with oligodeoxynucleotides eluting between 20 to 30 min (12% to 
18% acetonitrile) depending upon length and G-C content. The detection system 
consisted of continuous monitoring of sample absorbance at 254 run during 
analytical runs or at 280 nm during preparative runs. The peaks containing the 
full-length oligodeoxynucleotides were collected and evaporated to diyness as above. 
Finally, purified samples were resuspended in PBS at a concentration of 1 mM 
using Beer’s Law and an average nucleotide extinction coefficient of 10,000. 
Samples were stored at -20°C.
Synthesis and  Purification of Phosphorothioate Oligodeoxynucleotides.
Oligodeoxynucleotides with phosphorothioate linkages were synthesized using 
nucleoside 3’-hydrogen phosphonates as the starting reagents and 1- 
adamantanecarbonyl chloride as an activator (136,137,138) on an Applied 
Biosystems Model 380B. After automated detritylation, the oligonucleotides while 
still covalently attached to their solid support were treated with sulfurization 
reagents as specified by the manufacturer (139). Briefly, the synthesis cartridges 
were flushed for 3 hours at room temperature with a solution of 0.195 M S8 in 
48% (v/v) carbon disulfide, 48% (v/v) pyridine, and 4% triethylamine. Columns 
were then flushed twice with carbon disulfide, three times with 2% triethylamine 
in HPLC grade acetonitrile, and dried under vacuum. Modified oligonucleotides 
were then cleaved from the solid support with concentrated ammonium hydroxide 
and base deprotected with fresh concentrated ammonium hydroxide at 55°C for 10 
hours. Phosphorothioate DNA was desalted using the Sep-Pak protocol outlined 
above except that 60% acetonitrile in distilled water was used to elute samples 
owing to the increased hydrophobicity imparted by the phosphorothioate linkages.
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HPLC purification was completed under conditions similar to the above, except that 
buffer B= 100 mM TEAC + 60% acetonitrile and a linear gradient from 0% to 
100% "B" was run over 30 min. Under these conditions, de-protected 
phosphorothioate oligodeoxynucleotides elute at 12 to 15 min (24% to 30% 
acetonitrile) depending upon length and G-C content. Dried phosphorothioates 
were quantitated and resuspended at 1 mM in PBS as described above.
Serum  Stability of Oligodeoxynucleotides.
Synthetic DNA (1 ug) was first 5’-end labeled in a 10 ul reaction volume 
using 6.6 pmoles of “ P-gamma ATP and 1 unit of T4 polynucleotide kinase 
(Promega, Madison, WI) in a buffer containing 70 mM Tris-HCl (pH 7.6), 10 mM 
MgCl2, 0.1 mM KC1, 5 mM dithiothreitol, 1 mM spermidine, and 66 uM cold ATP 
at 37°C for 30 min. Labeled oligodeoxynucleotides were then incubated, as 
described, in various types of sera in the presence or absence of HL-60 cells for the 
indicated periods of time. Aliquots of samplss were removed, denatured in sample 
buffer (98% deionized form amide, 0.1% bromophenol blue, 0.1% xylene cyanole blue, 
10 mM EDTA), and analyzed by polyacrylamide gel electrophoresis. Samples 
incubated in the presence of cells were first centrifuged at 12,000 x g for 1 min 
to pellet cells before aliquots were taken.
Polyacrylam ide Gel Electrophoresis of Oligodeoxynucleotides.
End-labeled phosphodiester or phosphorothioate oligodeoxynucleotides were 
analyzed by electrophoresis on a sequencing gel (20% polyacrylamide, 7 M urea, 
90 mM Tris, 90 mM borate, 2 mM EDTA) at 300 volts. End-labeled 
oligonucleotide sizing markers from 8 bp to 32 bp were run as standards. Gels 
were fixed and desalted by soaking twice for 1 hr in a solution of 40% methanol,
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
50
10% glacial acetic acid, and 3% glycerol. Wet or dried gels were exposed to XRP- 
5 X-Omat film for autoradiography.
Cellular U ptake of Oligodeoxynucleotides.
End-labeled phosphodiester or phosphorothioate oligonucleotides (106 cpm/ml) 
were incubated with HL-60 cells (2 x 10® cells/ml) at 37°C. At indicated intervals, 
triplicate 200 ul aliquots were layered over 500 ul of a chilled (-20°C) mixture of 
dibutyl phthalate and dinonyl phthalate (75.3:24.7, v/v) and cells were pelleted 
through the oil by a 30 sec centrifugation in an Eppendorf microfuge. The aqueous 
and oil layers were aspirated and the tips of the tubes containing the cell pellets 
were cut off using dog toenail clippers. Total cell-associated radioactivity was 
assessed by liquid scintillation spectrometry. Duplicate samples were subjected to 
acid-washing after aspiration to remove membrane-bound counts (140). These 
samples were resuspended with 0.75 ml of either 0.2 M acetic acid and 0.5 M NaCl 
or 0.2 M glycine, vigorously vortexed, and incubated on ice for 5 min. Finally, the 
cells were pelleted by centrifugation and processed as described above. Cell- 
associated radioactivity remaining after acid-washing was considered to represent 
internalized oligodeoxynucleotides.
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Cell Proliferation and Differentiation.
Exposure of HL-60 cells to inducers of differentiation resulted in an 
inhibition of cell growth after different intervals of time that were characteristic 
of the agent employed (Fig. 3). The phorbol ester TPA caused the most rapid 
response, with cell stasis seen after only 12 hrs of treatment. Among the myeloid 
inducers, ACM and DMSO inhibited cellular proliferation after the briefest interval, 
with a cessation of growth occurring by 48 hrs. RA exhibited a more gradual 
effect, with cells displaying a loss of proliferative capacity only after 2 days of 
treatment. Changes in cell number are late consequences of any alteration to 
cellular proliferation status. Growth inhibition, alternatively, may be reflected 
earlier by changes in the proportion of S-phase cells by propidium iodide staining. 
However, significant changes in the DNA histograms of differentiating cells did not 
precede observed changes in proliferation status as assessed by cell number (Fig. 
4). A substantial shift to G/G, and away from S and Gj/M phases of the cell cycle 
were seen in TPA- and DMSO-treated cells a t 24 and 48 hrs, respectively. ACM 
appeared to cause an increase in S-phase cells at 24 hrs, with a subsequent 
accumulation of G</G, cells by 48 hrs. RA caused only minimal changes in cell 
cycle kinetics even at 48 hrs.
HL-60 cells are bipotent with respect to differentiation, being inducible along 
either the granulocytic or monocytic/macrophagic pathways. These processes may 
be quantitated by histochemical staining using NET dye reduction for granulocytic 
or monocytic (13) differentiation and non-specific esterase (NSE) activity for 
monocytic or macrophagic (125) maturation. In a manner analogous to that seen 
with cell replication, the kinetics of cellular differentiation varied with the inducer
51
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Figure 3. Cellular growth kinetics of untreated and differentiating HL-60 cells. 
Cells were exposed to vehicle (O); to granulocytic inducers, including 210 mM 
DMSO (®); 1 uM RA (A); and 40 nM ACM (®); or to 50 nM of the macrophagic 
inducer TPA (0). Cell numbers represent the mean of two determinations each 
from at least three experiments.
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Figure 4. Cell cycle profiles of untreated and differentiating HL-60 cells. Cells 
were treated with vehicle or to inducers of macrophagic or granulocytic 
differentiation. At the indicated times, cells were removed, fixed in ethanol, 
treated with RNase, and stained with propidium iodide. Histograms of relative 
cellular DNA content were obtained by fluorescence flow cytometry. The y-axis 
indicates cell number and the x-axis indicates increasing fluorescence signal. 
Panel A: Cells at 12 hr after exposure of inducers of differentiation. For
reference, the large peak seen with control cells represents G,/G, population. The
smaller peak represents the GJM. fraction. The area between the two peaks
approximates S-phase cells.
Panel B: Cells at 24 hr after exposure to inducers of differentiation.
Panel C: Cells at 48 hr after exposure to inducers of differentiation.
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employed (Fig. 5). RA and TPA were potent inducers of granulocytic and 
macrophagic differentiation, respectively, causing >90% of the cells to express the 
appropriate phenotypic markers after 4 days of exposure. The kinetics of 
granulocytic differentiation induced by DMSO and ACM differed slightly from that 
seen with RA, as shown by both the delayed onset of NBT positivity and the lower 
maximum number of mature cells. Untreated HL-60 cells exhibited minimal NBT 
reactivity during the course of the experiment. Similarly, control cells expressed 
<5% positivity for NSE throughout the measured time course (data not shown).
Although the aquisition of a mature phenotype was accompanied by the 
cessation of cellular proliferation, a strict temporal relationship between the two 
was not always apparent. Thus, significant NBT reducing activity was expressed 
and cell growth was inhibited virtually simultaneously after 48 hr in DMSO 
treated cells. However, the cessation of proliferation occurred long before the 
appearance of appropriate marker activities in cells induced to differentiate with 
TPA or ACM. Moreover, the relative rates of cellular maturation varied depending 
upon the particular marker assayed. Consistent with the findings of Rovera et al. 
(16), TPA-treated HL-60 cells acquired the ability to adhere to plastic. In our 
system, exposed cells first displayed adherence after only 8 hrs, with >90% of cells 
becoming adherent by 24 hrs (data not shown). These observations simply 
underscore the complexity of the differentiation process, during which a variety of 
cellular transformations must be completed, although not necessarily in an absolute 
sequential fashion.
Surface TfR Expression during Differentiation.
Cellular TfRs are localized in either internalized or surface membrane pools. 
Clearly the latter represent the more physiological relevant sub-population since
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Figure 5. Differentiation of HL-60 cells induced along the granulocytic and 
macrophagic inducers. HL-60 cells were exposed to vehicle (O); to granulocytic 
inducers, including 210 mM DMSO (®); 1 uM RA (A); and 40 nM ACM (®); or 
to 50 nM of the macrophagic inducer TPA (O), and differentiation was assessed by
nitroblue tetrazolium (--------) or nonspecific esterase (--------) staining. Points
represent mean ± S.E. of at least three experiments, each done in triplicate.







these receptors are actively involved in iron uptake and possible signal 
transduction functions. Surface TfR expression can be conveniently assessed by 
direct immunofluorescence using a fluorescein-labeled monoclonal antibody against 
the human TfR. Cells stained in this manner can be analyzed for relative cellular 
sTfR levels by use of a fluorescence activated cell sorter (FACS). Typical 
fluorescence histograms for uninduced, BMSO-treated, and RA-treated HL-60 cells 
in which fluorescence intensity is plotted on a logarithmic scale are shown in 
Figure 6. Uninduced cells stained with the labeled antibody are generally 80-100 
fold more fluorescent than are non-stained cells. For quantitative comparisons, the 
mean fluorescence intensity for differing populations of cells is interpreted as the 
relative level of cellular sTfR expression for that population.
The expression of sTfR in untreated HL-60 cells was not constant, but 
instead appeared to be correlated with the cellular proliferative status. After 5 
days in culture, control cells no longer exhibited replicative activity and sTfR levels 
decreased by 10-foid, compared to that seen at the beginning of the experiment 
(Fig. 7). However, even during the exponential phase of cell growth, receptor 
expression was reproducibly altered. Consistent with the observations of Taetle et 
al. (65), a biphasic change in surface receptors was seen during the first four days 
of the experiment, when untreated control cells were increasing exponentially. A 
virtual doubling of the levels of sTfR occurred during the first 24 hrs, followed by 
a gradual return to initial levels during the next 3 days. It should be stressed 
that the HL-60 cells employed in the present experiments were passaged at four 
day intervals to ensure exponential growth, hence the initial rise in sTfR was not 
a consequence of a stationary to growth phase transition of the cell cultures.
The relative amounts of membrane-associated TfR declined at various rates 
when HL-60 cells are induced to differentiate. In agreement with the results of
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Figure 6. FACS profiles of sTfR expression in untreated and differentiating HL- 
60 cells. Cells were exposed to vehicle or to inducers of granulocytic differentiation 
for the indicated intervals. Cells were then incubated with a fluorescein 
isothiocyanate-conjugated murine monoclonal anti-TfR antibody at 4°C and fixed 
in 2% paraformaldehyde in PBS under conditions specified by the manufacturer. 
Samples were analyzed by fluorescence flow cytometry.
Tracings at right represent cellular fluorescence. Results are expressed with 
increasing fluorescence intensity on the x-axis and absolute cell number on the y- 
axis. Uninduced cells (black), DMSO-treated cells (red), RA-treated cells (orange).
Tracings at left represent forward scatter which approximates cell size. 
Upper Panel: Cells at 8 hr.
Lower Panel: Cells at 24 hr.
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Figure 7. Down-regulation of sTfR in untreated and differentiating HL-60 cells. 
HL-60 cells were exposed to vehicle (O); to granulocytic inducers, including 210 
mM DMSO ( ® ); 1 uM RA (A ); and 40 nM ACM (♦ ) ;  or to 50 nM of the 
macrophagic inducer TPA (•) . Receptor expression was assessed as in Figure 6 
with cellular autofluorescence substracted from anti-human TfR antibody-related 
fluorescence. Points represent the mean of at least two experiments.

















May et al. (50), exposure to TPA elicited an extremely rapid reduction in receptor 
expression. They demonstrated that ,26I-transferrin binding decreased by 50% after 
only 60 min of TPA treatment. We have found that continued exposure to the 
phorbol ester results in a further down-regulation of sTfR in excess of that 
previously reported by May et al. (141). Although an overall 16-fold reduction in 
surface receptor was observed during the entire course of the exposure to TPA, 
most of this decrease in receptor expression occurred during the first 4 hrs of 
induction.
The inhibition of TfK expression during myeloid differentiation occurred 
more gradually, although levels of surface receptors ultimately declined to the 
quantity present in TPA-treated cells. Treatment of HL-60 cells with DMSO 
always caused a minimal increase in sTfR levels during the first 8 hrs followed by 
a pronounced decline, during which receptor levels approximated those of TPA 
induced cells after 48 hrs. RA reduced sTfR levels by 25% after only 4 hrs; 
however, the subsequent inhibition of receptor expression occurred more slowly 
than that seen with DMSO. ACM induced the most rapid decrease in surface 
receptor activity among the myeloid inducers, with a 50% decrease in TfR being 
obtained after 10 hrs.
Alternatively, cellular sTfR activity may be assessed by radioligand binding 
at 4°C using ,2SI-Tf. Direct immunofluorescence using the Becton-Dickensen 
monoclonal antibody and 12SI-Tf binding provided comparable results. The extent 
of TfR down-regulation during the induction of granulocytic differentiation with 
DMSO or RA, as assessed by these two techniques, was quite consistent (Table 1).
Although a direct relationship between TfR expression and cellular 
proliferative capacity has been demonstrated in other model systems (43,45), it 
remains unclear whether sTfR modulation in differentiating leukemia cells is more
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TABLE 1
HL-60 sTfR Activity A ssessed  by 
12Sl-Transferrin Binding or a Monoclonal Anti-TfR Antibody 
During Granulocytic Differentiation





















Cells were treated with inducers or vehicle for the indicated time intervals and 
sTfR was assessed  by the two indicated methods. DMSO was employed at 
175 mM for the ligand binding studies and at 210 mM for the fluoresceinated 
antibody assays. RA was used at 1 uM. Values in parentheses represent 
percentage of control.
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closely associated with the programmed termination of cellular replicative capacity 
or with the initiation of the maturation process itself. The kinetics of sTfR down- 
regulation in differentiating cells differed markedly depending upon the inducer 
employed. These relationships were quantitatively assessed by comparing the 
duration of exposure to inducer which is required before significant cellular 
alterations were observed. A four-fold decrease in sTfR, cessation of proliferation, 
and the appearance of a mature phenotype in 25% of cells were arbitrarily chosen 
as representative indices of the terminal differentiation process. Table 2 shows the 
extrapolated durations before each of these milestones were reached in induced 
cells. A temporal relationship existed between receptor down-regulation and the 
eventual inhibition of growth, with the former always preceding the latter by 10 
to 16 hrs. TPA, which down-regulated sTfR most rapidly, inhibited cellular 
proliferation in the shortest period of time. In contrast, RA exhibited the most 
gradual effects on receptor expression and cell growth, with ACM and DMSO 
evidencing an intermediate action. The temporal relationship between receptor 
expression and the differentiated phenotype demonstrated pronounced inducer- 
related variability and, in one case (RA), the appearance of the mature phenotype 
preceded a significant reduction in sTfR levels.
TfR Message Levels during  Differentiation.
Initial investigations of TfR mRNA levels using dot blot analyses suggested 
that alterations in surface receptor are preceded by specific changes in transcript 
levels. When total cellular RNA was covalently linked to nylon membranes and 
hybridized to a “P-labeled cDNA probe for the human TfR, an increase in the 
relative amount of receptor message was apparent upon the subculturing of 
uninduced HL-60 cells (Fig. 8). TfR mRNA peaked at 12 hrs, at which time
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
TABLE 2
69
Effect of the Duration of Exposure to Inducers of Differentiation 
on sTfR Down-regulation, Growth Inhibition, and Granulocytic and 
Macrophagic Maturation of HL-60 Ceils
Time (hrs)
Treatment sTfR (25%) Growth Inhibition Maturation (25%)
DMSO (210 mM) 38.2 48.0 58.6
RA (1 uM) 57.4 72.0 38.7
ACM (40 nM) 32.6 48.0 62.5
TPA (50 nM) 3.8 12.0 46.9
The time intervals required for the appearance of representative indices of HL- 
60 leukemia cell differentiation, including: sTfR expression decreases to 25% 
of initial values; cessation of cellular proliferation; and appearance of lineage 
specific enzymatic activity in 25% of the total cell population, were derived from 
Figures 3, 5, and 7.
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Figure 8. Dot blot of TfR and B-actin mRNA in untreated and DMSO-treated HL- 
60 cells. Twenty ug and successive 1:2 dilutions of total cytoplasmic RNA from 
cells grown in the absence or presence of DMSO (210 mM) were covalently bound 
to a Gene Screen filter, hybridized with ^-labeled TfR probe, and subjected to 
autoradiography. The filter was then stripped of remaining probe, rehybridized 
with a ^-labeled probe to B-actin, and autoradiographed.
R eproduced with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
Time(hr) DMSO TfR /3-Actin
0  —  *
4  — ®
4  +  »
8 — ® . #  *
8 + #  ■*. -
12 -  #  m #  ®
12 + #  #■
24 -  #  . #  # ,
#►£ *24 +  * •
36  — #
36  +
48  — «
48  +
R eproduced with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
72
approximately twice the amount of receptor transcript was present compared to 
initial values. That the increase in TfR message was of the same magnitude as 
and preceded the rise in surface protein suggested that the later event was 
biosynthetically mediated at the mRNA level. As a control, the dot blot 
membranes were stripped of the TfR probe and rehybridized with a labeled cDNA 
probe to B-actin. No significant changes were seen in the levels of B-actin gene 
expression through 48 hrs in non-induced cells, indicating that changes in TfR 
message were specific and were not a consequence of sample loading variability.
More detailed analyses of cellular transcript levels were possible by size 
fractionation of ENA using denaturing gel electrophoresis followed by northern blot 
hybridization. This technique permitted identification of mRNA species based upon 
the expected molecular size of the transcript and ensured that excessive 
degradation of RNA samples had not occurred. Previous work by Kuhn et al. (57) 
has shown that TfR specific mRNA is 4.9 kb in length and migrates slightly above 
the 28S ribosomal RNA band on formaldehyde/agarose gels. The TfR cDNA probe 
did indeed hybridize with message at the expected molecular weight as shown in 
Figure 9. The appearance of minor hybridizing transcripts is probably artifactual 
and represents degradation of the TfR message. The area between the smaller 
bands and the main TfR band corresponded exactly to the location of the 28S 
ribosomal species. The overwhelming abundance of rRNA in this region may have 
interfered with probe hybridization to the expected TfR mRNA degradative species. 
Furthermore, consistent with our previous results using dot blot analysis, DMSO 
induction led to a specific decrease in the amount of TfR transcripts (Table 3). No 
significant change in message levels were seen until 8 hrs of treatment, whereupon 
TfR specific transcripts declined dramatically through 24 hrs and remained minimal 
through 48 hrs. Digital densitometry indicated that the steady-state levels of TfR
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Figure 9. Northern blot of TfR and B-actin mRNA in untreated, DMSO-, RA-, 
and TPA-treated HL-60 cells. Ten ug of total cytoplasmic RNA from cells treated 
for the indicated intervals with vehicle, DMSO (210 mM), RA (1 uM), or TPA (50 
nM) were size fractionated in a 1.2% agarose/formaldehyde gel, transferred onto 
Gene Screen filters, hybridized with '^P-labeled probes specific for TfR and B-actin, 
and subjected to autoradiography.
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Densitometric Quantitation of Relative mRNA Levels during 
Granulocytic and Macrophagic HL-60 Cell Differentiation













The autoradiogram shown in Figure 9 was scanned by digital densitometry and 
the results are expressed as a  ratio of the TfR to B-actin values.
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mRNA declined to 50% of initial levels by 12 hrs of DMSO exposure. Comparison 
with Figure 7 indicates that this decrease in transcripts preceded by 12 hrs similar 
reductions at the protein level. Since B-actin mRNA is 2 kb, hybridization with 
both the TfR and B-actin probes can be performed simultaneously. In a manner 
analogous to that seen in uninduced cells, levels of B-actin transcripts did not 
change appreciably during the first 48 hrs of DMSO treatment. In addition, 
DMSO and the other inducers used did not significantly alter the cellular 
ribosomal RNA content, as visualized by staining agarose/formaldehyde gels with 
acridine orange (data not shown).
Consistent with the gradual decline in surface TfR in RA-induced cells, the 
reduction in steady-state levels of receptor transcripts was a relatively late event. 
Interestingly, the amount of TfR message in these cells increased in parallel to 
that seen with control cells during the first 8 hrs of treatment. This finding 
contrasted with the slight reduction in surface receptor levels seen during this 
period. RA-treated cells began evidencing decreased levels of TfR transcripts 
relative to control by 12 hrs, with the most pronounced reduction occurring by 48 
hrs, when sTfR was also markedly down-regulated.
ACM produced an immediate reduction in TfR message (Figure 10, Table 4). 
When equivalent time points were compared to sTfR expression (Figure 7), the 
decline in TfR transcripts, as quantitated by densitometry, were seen to precede 
that occurring at the protein level by 4 hrs, suggesting that the TfR down- 
regulation was at least in part mediated by a reduction in the steady-state level 
of mRNA. The inhibitory effects of this anthracycline on lipid-linked 
oligosaccharide biosynthesis have been indirectly implicated as a postulated 
mechanism of the decreased sTfR activity by Morin et al. (49). In fact, 
granulocytic differentiation by DMSO, RA, and ACM appear to have as a common
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Figure 10. Northern blot of TfR and B-actin mRNA in untreated and ACM- 
treated HL-60 cells. Ten ug of total cytoplasmic RNA from cells treated for the 
indicated intervals with vehicle or ACM (40 nM) were size fractionated in a 1.2% 
agarose/formaldehyde gel, transferred onto Gene Screen filters, hybridized with 32P- 
labeled probes specific for TfR and B-actin, and subjected to autoradiography.
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Densitometric Quantitation of Relative mRNA Levels during 
ACM-induced Granulocytic Differentiation of HL-60 Leukemia Cells
TfR/Actin Ratio 







The autoradiogram shown in Figure 10 was scanned by digital densitometry and 
the results are expressed as a  ratio of the TfR to 13-actin values.
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attribute the down-regulation of sTfR, which is kinetically compatible with reduced 
receptor biosynthesis secondary a decrease in TfR transcript levels.
In contrast to the above findings, the initial down-regulation of sTfR during 
macrophagic differentiation by TPA (Figure 9, Table 3) was clearly not attributable 
to reduced transcripts. In fact, an increase in TfR mRNA occurred through the 
first 12 hrs in spite of drastic reductions in surface receptor content, which 
presumably resulted from an intracellular redistribution. May et al. have 
demonstrated that this phorbol ester-induced receptor redistribution does not result 
in any alteration in the total amount of cellular TfR protein (50).
Alternatively, an increased rate of TfR protein catabolism may contribute to 
the down-regulation of TfR seen during differentiation. This hypothesis was tested 
by pulse-chase labeling of whole cells with “S-methionine. After a 4 hr pulse, HL- 
60 cells were washed free of the metabolic label and resuspended into medium 
containing cold methionine. During the 24 hr chase period, cells were periodically 
lysed and TfR protein half-life was monitored by immunoprecipitation and SDS- 
polyacrylamide gel electrophoresis. An increase in the turnover of TfR protein was 
not seen in DMSO-treated cells over uninduced cells (Fig. 11). This finding 
supports the view that biosynthetic alterations, perhaps relating to transcriptional 
regulation, underlie the down-regulation of TfR seen during the chemically-induced 
differentiation of HL-60 leukemia cells.
Monocytic D ifferentiation Induced by 10 ,2  5-dihydroxy vitam in D„.
Monocytic maturation, in contrast to granulocytic and macrophagic 
differentiation, is not, by definition, a terminal differentiation program. Although 
these cells may express mature phenotypic markers, irreversible loss of proliferative 
potential is not a concomitant event. Indeed, HL-60 cells continuously exposed to
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Figure 11. TfR protein half-life in untreated and differentiating HL-60 cells. 
Cells were pulse labeled with “S-methionine for 4 hours and chased in culture 
media containing cold methionine for the indicated intervals. Lysates, prepared by 
solubilizing whole cells with 0.5% NP-40, were then immunoprecipitated with a 
murine monoclonal anti-human TfR antibody and protein-A-agarose. Samples were 
finally analyzed by SBS-polyacrylamide gel electrophoresis and fluorography.
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100 nM la,25-dihydroxyvitamin D3 for 6 days exhibited the same proliferative rate 
as untreated controls (Fig. 12). Induced cells did differentiate as evidenced by the 
progressively increased percentage of cells expressing the differentiation markers, 
NBT and NSE (Fig. 13). In contrast with macrophagic maturation induced by 
TPA, la,25-dihydroxyvitamin D3-treated HL-60 cells weakly expressed non-specific 
esterase activity and did not adhere to plastic. Down-regulation of sTfR was a 
relatively late event in this system. A signficant difference between induced and 
uninduced cells was evident only after 48 hr of exposure (Fig. 14). More 
importantly, a decrease in sTfR expression to 25% of initial levels (see Table 2) 
was apparent only during the last day of the experiment. Observed in both 
uninduced and treated cells, this late TfR down-regulation event is probably 
secondary to plateau phase growth due to high density culture conditions.
These experiments with lo,25-dihydroxyvitamin D3 support the preceding 
hypothesis that TfR down-regulation during the terminal differentiation of HL-60 
cells is more closely associated with cessation of cellular proliferation than with the 
acquisition of the mature phenotype. A significant and early down-regulation of 
TfR in induced cells was not apparent during monocytic differentiation with la ,25- 
dihydroxyvitamin D3. Consequently, although HL-60 cells induced with this agent 
expressed enzymatic activities and morphology characteristic of monocytes, cell 
growth was not inhibited.
Calcium Channel Blockers Potentiate TfR Down-Regulation by Inducers 
of Differentiation.
It has been previously noted that TfR induction is a requisite event during 
the activation of T-lymphocytes by mitogens (45). In normal resting T-cells, the 
TfR gene is transcriptionally silent. The mitogenic stimulus provided by
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Figure 12. Growth kinetics of HL-60 cells induced with la,25-dihydroxyvitamin 
Da. Cells were treated with vehicle or 100 nM la,25-dihydroxyvitamin D3. Cell 
counts were determined as described in the legend to Figure 3.
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Figure 13. Differentiation of HL-60 cells induced with la,25-dihydroxyvitamin D3. 
Cells were treated with vehicle or 100 nM la,25-dihydroxyvitamin D3. 
Differentiation was assessed on days 3 and 6 by NET or NSE staining as described 
in the legend to Figure 5.
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Figure 14. sTfR alterations in HL-60 cells induced with la,25-dihydroxyvitamin 
D3. Cells were treated with vehicle or 100 nM la,25-dihydroxyvitamin D3. sTfR 
was assessed at daily intervals as described in the legend to Figure 7.
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phytohemagglutinin and phorbol esters results in the sequential activation of the 
genes for the interleukin-2 receptor and T£R. Further dissection of this system has 
revealed that calcium plays a role in the regulation of lymphocyte proliferation. 
Mobilization of intracellular calcium and an influx of extracellular calcium are seen 
during mitogenesis. In some instances, the calcium ionophore A23187 may 
substitute for the requirement for tissue-specific growth factors, such as 
interleukin-2 (142). These observations led Neckers et al. to investigate the effects 
of diltiazem, a calcium channel blocker, on the T-cell activation cascade (143). 
Diltiazem at 100 uM was found to prevent the induction of TfR mRNA and protein 
in normal T-cells and caused a progressive loss of TfR mRNA and protein in a 
malignant T-cell line. Cells treated by this agent subsequently exhibited growth 
arrest in the G, phase of the cell cycle. These phenomena were also observed in 
cells treated with EGTA, further supporting the role of calcium in the induction 
of TfR biosynthesis during T-lymphocyte activation.
Since both diltiazem and the inducers of leukemia cell differentiation 
inhibited TfR expression, we attempted to determine if these agents would 
synergistically act to down-regulate TfR expression in HL-60 cells. As shown in 
Table 5, diltiazem or verapamil at 100 uM as well as diltiazem at 50 uM markedly 
inhibited sTfR expression. The addition of sub-optimal concentrations of 
differentiation inducers, including RA at l/100Qth of the usual inducing dose, 
resulted in an additive suppression of surface TfR. These data raise the 
interesting possibility of using combinations of agents, perhaps including calcium 
channel blockers, which inhibit TfR expression by independent mechanisms to 
potentiate the inhibition of proliferation of neoplastic cells.
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Synergistic  Effect of Calcium Channel B lockers and 
Sub-optim al C oncentrations of Differentiation Inducers 
on HL-60 sTfR Levels
125l-Tf bound (% of Control)
Diltiazem Diltiazem Verapamil
Inducer Control (50 uM) (100 uM) (100 uM)
None 100 41.0 25.3 11.8
RA - 1 nM 49.7 22.1 14.7 n.d.
DMSO - 0.5% 22.5 8.8 3.1 n.d.
DMSQ - 0.75% 9.1 n.d. 8.1 3.5
Cells were treated with vehicle, inducers, or calcium channel blockers for 
4 days. Relative sTfR levels were assessed  by steady-state cellular binding of 
125l-Tf at 4°C.
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Uridine and Thymidine Incorporation.
To determine whether the down-regulation of TfR mRNA seen during the 
chemically-induced differentiation of HL-60 cells was a result of a non-specific 
suppression of RNA synthesis, cells were pulse labeled with *H-uridine and assayed 
for incorporation of the radiolabeled nucleotide into macromolecules. A significant 
inhibition in ^-uridine incorporation was not seen until after 24 hr in cells treated 
with DMSO (Fig. 15). It may be recalled that TfR transcript levels began to 
decline as early as 8 hr after the exposure of cells to DMSO (Table 3). Similarly, 
cells treated with RA incorporated *H-uridine at levels similar to that of control 
cells even after 48 hr of exposure. In contrast, the level of TfR message in RA- 
treated cells at 48 hr were 15% that of control cells (Table 3). Clearly, the 
decreases noted in the level of steady-state TfR transcripts were specific and did 
not result from a generalized inhibition in RNA synthesis during the differentiation 
of these cells. The rate of 3H-thymidine incorporation in these cells is shown for 
reference (Fig. 16). Relative to uninduced cells, differentiating cells exhibited 
decreased levels of 3H-thymidine incorporation before equivalent changes were seen 
in the levels of 3H-uridine incorporation.
Modulation of Growth and Differentiation by Iron and Iron Chelator.
The results presented above suggested that the down-regulation of TfR seen 
during the terminal differentiation of HL-60 cells was more closely associated with 
cessation of cellular proliferation than with acquisition of the mature phenotype. 
Since the primary role of TfR is to mediate iron uptake into cells, we asked 
whether manipulation of iron availability, through the addition of exogenous iron 
or iron chelators, would affect the induction of differentiation. Specifically, since 
agents such as DMSO and RA promote TfR down-regulation, which leads to
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Figure 15. 3H-tJridine incorporation during granulocytic and monocytic 
differentiation. Cells were removed after exposure to inducers for the indicated 
intervals, pulse-labeled for 1 hr with 2 uCi 3H-uridine, washed with PBS, and 
collected on Whatman GF/C filters. Cellular macromolecules were precipitated with 
ice-cold 10% trichloroacetic acid. Filters were washed with distilled water and 
ethanol and then quantified by liquid scintillation spectrometry. Data represent 
the mean ± S.D. of triplicate determinations.
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Figure 16. ‘’H-Thymidine incorporation during granulocytic and monocytic 
differentiation. Cells were removed after exposure to inducers for the indicated 
intervals, pulse-labeled for 1 hr with 2 uCi ^-thymidine, washed with PBS, and 
collected on Whatman GF/C filters. Cellular macromolecules were precipitated with 
ice-cold 10% trichloroacetic acid. Filters were washed with distilled water and 
ethanol and then quantified by liquid scintillation spectrometry. Data represent 
the mean ± S.D. of triplicate determinations.
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decreased cellular iron uptake and terminal differentiation, would increasing the 
amount of bioavailable iron to cells inhibit differentiation?
Varying concentrations of bioavailable iron, present in a molar ratio of 1:2 
with nitriloacetate, were added to HL-60 cells exposed to 210 mM DMSO or to 
vehicle. A biphasic effect on cellular growth was seen (Fig. 17, upper panel). At 
concentrations up to 10 uM FeCl3, cell growth was stimulated by up to 50%. From 
10 uM to 1 mM of FeCl3, however, a dose dependent inhibition of cell growth was 
apparent. Evident in both control and induced cells, this was presumably related 
to iron toxicity. In contrast, addition of iron did not significantly modify the 
induction of NET positivity by DMSO throughout the concentration range tested 
(Fig. 17, lower panel).
The inverse question may be asked. Does the simulation of TfR down- 
regulation by chelation of extracellular iron with deferrioxamine (Desferal) induce 
maturation by itself or enhance differentiation using sup-optimal concentrations of 
inducers? Thus, cells induced with optimal doses of DMSO (210 mM) or RA (luM) 
or with sub-optimal doses (105 mM DMSO or 1 nM RA or 10 nM RA) of 
differentiating agents were exposed to concentrations of Desferal up to 10 uM. 
Regardless of the presence or absence of DMSO or RA, cells exposed to 10 uM 
Desferal proliferated at a rate approximately 25% that of untreated cells (Fig. ISA, 
upper panel; Fig. 18B, upper panel). The growth inhibitory effects of the iron 
chelator were dose dependent. Desferal, like exogenous FeCl3, did not appreciably 
alter the degree of maturation observed with varying doses of inducers of 
differentiation (Fig. 18A, lower panel; Fig. 18B, lower panel).
These results support the hypothesis that a consequence of TfR down- 
regulation during the terminal differentiation of HL-60 cells is the inhibition of 
growth without attendent effects on cellular maturation. The reduction of
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Figure 17. Effect of exogenous Fe on HL-60 growth and differentiation. Cells 
were exposed to 210 mM DMSO or vehicle and to varying concentrations of 
FeCl3:nitriloacetate (1:2) for 5 days.
Upper panel: Cell proliferation
Lower panel: Differentiation as assessed by NBT staining. Values represent the 
mean ± S.D. of triplicate determinations.
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Figure 18. Effect of deferrioxamine on HL-60 growth and differentiation. Cells 
were exposed to vehicle or inducers of granulocytic differentiation at the indicated 
concentrations and to varying concentrations of the iron chelator, deferrioxamine 
(Desferal), for 4 days. Cell growth and differentiation was assessed by methods 
described in Figure 17 legend.
A (Upper panel): Desferal and DMSO. Cell proliferation.
A (Lower panel): Desferal and DMSO. Cell differentiation. Values represent the 
mean ± S.D. of triplicate determinations.
B (Upper panel): Desferal and RA. Cell proliferation.
B (Lower panel): Desferal and RA. Cell differentiation. Values represent the 
mean ± S.D. of triplicate determinations.
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bioavailable iron to the cell through TfR down-regulation or extracellular Desferal 
did not increase the number of NBT positive cells, either alone or in concert with 
DMSO or RA. Conversely, the addition of exogenous iron, up to toxic levels, did 
not inhibit the ability of DMSO, which reduces levels of sTfR, to induce 
maturation. However, manipulation of extracellular iron levels markedly 
modulated the cellular growth of uninduced and induced cells. Iron 
supplementation up to 10 uM stimulated growth, whereas iron chelation resulted 
in marked growth inhibition.
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Biological Efficacy of Phosphodiester Antisense Oligonucleotides.
The hypothesis that TfR down-regulation triggers the inhibition of cell 
growth without inducing phenotypic differentiation in HL-60 cells is inferential. 
The arguments presented above rest on temporal associations and involve the use 
of differentiation agents which may have multiple actions within the cell in 
addition to down-regulating sTfR. Clearly, the diverse chemical classifications 
which encompass the inducers of differentiation, ie. DMSO, RA, ACM, TPA, la ,25- 
dihydroxyvitamin D3, suggest that they may possess a disparate spectrum of 
biochemical activities in the cell. In order to employ a novel alternate means of 
specifically inhibiting sTfR expression, antisense oligonucleotides were generated 
against the human TfR mRNA.
The TfR mRNA is organized into a 2.3 kb coding sequence, flanked by 0.28 
kb and 2.6 kb untranslated regions at the 5’ and 3’ ends, respectively (57,59). 
Antisense oligonucleotides of 17- and 30-mer length were synthesized against target 
sites in the regions of the initiation codon, a 5’ upstream site at -50 bp relative to 
the initiation codon, and the 5’ cap site of the TfR mRNA (Fig. 19). In many 
cases, identical sequences in the phosphodiester and phosphorothioate series of 
oligomers were generated. Sense oligomers or scrambled sequence oligomers in 
which the final base composition of the molecules was unchanged from its 
antisense congener were synthesized as presumptive negative controls. In addition, 
previously well-characterized antisense oligonucleotides directed against c-myc and 
VSV target sites were also synthesized (91).
Mathematical algorithms have been developed to predict folding of single 
stranded RNA based upon thermodynamic considerations (144,145). A two- 
dimensional map showing the theoretical folding of the first 1000 bases of the 
human TfR mRNA revealed extensive secondary structure and potential sites of
R e p ro d u c e d  with perm iss ion  of th e  copyright ow ner.  F u r th e r  reproduction  prohibited without perm iss ion .
105
Figure 19. Human TfR mRNA map and sequences of antisense 
oligodeoxyribonucleotides.
Top. A map of the human TfR mRNA is shown schematically. The 2.3 kb coding 
sequence is flanked at the 5’ end by a 0.3 kb untranslated segment and at the 3’ 
end by a 2.6 kb untranslated region. The target sites of antisense oligonucleotides 
are shown with nucleotide sequence numbers expressed relative to the initiation 
codon.
Bottom: The antisense oligonucleotides employed in these experiments along with 
their target site, sequence data, and intemucleotide bond type are indicated. 
Normal phosphodiester oligomers are denoted as PO, whereas phosphorothioate 
analogues are denoted as PS. Antisense, sense, and scrambled sequence oligomers 
were synthesized. The number of mismatched bases in the scrambled sequence 
oligomers are denoted. Antisense DNA against TfR were 17 or 30 bases in length; 
oligonucleotides against c-myc or VSV were 15-mers.




TfR coding sequence 3' untranslated 
region
I  1 30
initiation codon: ATG ATG GAT CAA GCT AGA TCA GCA TTC TCT
-51 -22
5’ upstream: GCT GTG GCG GCG CCT CGA GCG GCT GCA GGT
-282 -266 
cap site: GAG CGT CGG GAT ATC GG
Location Oliaomer Seauence linkaae I m
Initiation codon TF1 CTA GCT TGA TCC A TC AT PO Anti-sense
TTF1 tt PS "
TTF9 CTA  ACT TCA ACC TTG  GT PS Mismatch (6)
T1S ATG A TG  GAT CAA GCT AG PO Sense
TT1S t t PS
TTF5 AGA GAA TGC TGA TC T AGC TTG ATC CAT CAT PS Anti-serise
TTF6 AGA GAA CGT TCT TC T ATC TTG AAG ACA CGT PS Mismatch (11)
5’ upstream TF2 CGA GGC GCC GCC ACA GC PO Anti-sense
TTF2 *• PS "
TTF4 ACC TGC AGC CGC TCG AGG CGC CGC CAC AGC PS it
Cap site TTF7 CCG ATA TCC CGA CGC TC PS Anti-sense
TTF8 CCG ACA T T C  CGT CCC GA PS Mismatch (6)
Init. codon- Myc MY1 AAC G TT GAG GGG CAT PO Anti-sense
TMY1 t t PS 1
MYS ATG CCC CTC AAC GTT PO Sense
TMYS f t PS
Init. codon-VSV VSV TTG  GGA TAA CAC TTA PO Anti-sense
Random sequence TTGT TGT GTG TGT GTG TGT GT PS Random
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intramolecular hybridization (Fig. 20). Presumably, large stem loop structures 
present on transcripts should provide attractive targets for antisense inhibition of 
gene expression since contiguous segments of single stranded mRNA are available 
for heteroduplex formation. For example, the TfR initiation codon occurs several 
bases proximal to a large potential stem loop structure, indicated between bases 
270 and 280 in Figure 20. The antisense oligomer, TF1, was designed to hybridize 
to this region of message.
Initial experiments focused on the effects of phosphodiester antisense 
molecules on sTfR expression and cellular proliferation in the parental HL-60 cell 
line which was grown in serum-containing culture medium. Three antisense 
molecules were first assessed for activity. MY1 was identical to the anti-myc 
pentadecamer employed by Wickstrom (91) and Holt (92). TF1 and TF2 were, 
respectively, 17-mers targeted to the initiation codon and a 5’-upstream region at 
-50 bases from the initiation codon of the human TfR mRNA. A surprising range 
of biological efficacy was evident when these phosphodiester oligonucleotides were 
tested for activity. At 50 uM, MY1 had little effect on cellular proliferation and 
sTfR expression, whereas TF1 inhibited sTfR levels by greater than 80% after 24 
hr and suppressed cell growth by 90% after 72 hr compared with vehicle-treated 
controls (Fig. 21). TF2 displayed an intermediate effect. Surprisingly, cell 
viability, as assessed by trypan blue exclusion after 72 hr of oligomer exposure, 
parallelled the levels of growth inhibition. This suggested that the mechanism of 
growth inhibition might be frank cytotoxicity by the oligonucleotides or by an 
unknown contaminant. These initial experiments employed oligonucleotides which, 
other than being lyophilized twice, were not purified after recovery from the DNA 
synthesizer. This strategy was based upon some of the early antisense literature 
which described the use of oligonucleotides prepared in this manner as appropriate
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Figure 20. Theoretical folding of TfR mRNA molecule. The first 1000 bases from 
the Genbank file HUMFTRRA, which contains the sequence for the human TfR 
cDNA, were evaluated by the FOLD algorithm of Zucker (144,145). The resultant 
predicted secondary structure was plotted using the SQUIGGLES program. 
Computer-derived manipulations were performed using the Sequence Analysis 
Software Package from the Genetic Computer Group at the University of Wisconsin 
Biotechnology Center.
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Figure 21. Effect of crude TfR antisense oligodeoxyribonucleotides on HL-60 
growth, viability, and sTfR. HL-60 cells grown in FBS-containing medium were 
exposed to vehicle or to 50 uM oligomer. Levels of sTfR were assessed by binding 
of a fluoresceinated anti-human TfR monoclonal antibody after 24 hr exposure to 
oligonucleotide. Cell counts and cell viability was assessed after 72 hr incubation 
with oligonucleotide.
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reagents for tissue culture (98).
To distinguish between oligonucleotide-mediated growth inhibition versus 
cytotoxicity, the oligonucleotides were digested with DNase I prior to incubation 
with HL-60 cells. The rationale for this experiment was that if the biological 
activity of the oligonucleotides was mediated by an antisense mechanism, then 
DNase I digestion should abolish any biological effect of these oligomers. Retention 
of significant sTfR or growth inhibitory activity after enzymatic hydrolysis of these 
molecules would suggest that these effects were not being mediated by the 
oligonucleotides as antisense agents. Short oligonucleotides can be analyzed and 
sized by denaturing gel electrophoresis using polyacrylamide gels impregnated with 
7M urea. These denaturing conditions are crucial in permitting the separation of 
oligonucleotides based primarily on size considerations since intrastrand folding of 
DNA may result in artifactual rates of electrophoretic migration.
The undigested parental oligomers appeared as distinct single bands at the 
expected molecular weights, suggesting that their synthesis proceeded with high 
coupling efficiencies and that they were free of prematurely terminated species 
(Fig. 22, lanes 2,5,10-12). Exposure of the oligomers to DNase I resulted in 
substantial digestion of the parental 15- or 17-mers to sequences smaller than 7- 
mers using high concentrations of enzyme (Fig. 22, lanes 3 & 6) or smaller than 
or equal to 9-mers using low concentrations of enzyme (Fig. 22, lanes 4 & 7). 
These short sequences should be too short to specifically interact with single target 
sites within the eukaryotic genome, hence should not possess intrinsic antisense 
activity. However, these hydrolyzed oligonucleotides displayed comparable levels 
of growth inhibition with that of the undigested species (Fig. 23). This suggested 
that the original observations noted in Figure 21 were not mediated by the 
oligonucleotides as antisense agents. Since initial purification was not performed
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Figure 22. Electrophoresis of DNase I digested TfR antisense 
oligodeoxyribonucleotides. Synthetic DNA was hydrolyzed with DNase I from 
Promega (1 U/ul) or from Worthington Biochemicals (12.5 U/ul) for 3 hr at 37°C, 
5-end labeled with T4 polynucleotide kinase and ^-A TP, and analyzed by 
denaturing polyacrylamide gel electrophoresis and autoradiography.
Lane 1 & 9: Oligonucleotide sizing markers.
Lane 2 & 11: TF1, undigested.
Lane 3: TF1, digested with DNase I (Worthington).
Lane 4: TF1, digested with DNase I (Promega).
Lane 5 & 12: TF2, undigested.
Lane 6: TF2, digested with DNase I (Worthington).
Lane 7: TF2, digested with DNase I (Promega).
Lane 10: MY1, undigested.
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Figure 23. Effect of DNase I pre-treatment on TfR antisense activity. Crude and 
hydrolyzed oligomers prepared as described in Figure 22 legend were incubated 
with HL-60 cells in FBS-containing medium at 50 uM for 3 days. Cell number 
and viability was determined as described in Figure 21 legend.
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on these oligomers, it was possible that a contaminant from the synthesis of the 
oligonucleotides, perhaps an organic salt or cleaved protecting group, remained as 
a cytotoxic agent responsible for the biological effects seen.
HPLC Purification o f Oligonucleotides.
The purification of synthetic oligonucleotides as potential antisense agents 
was deemed necessary due to the artifactual results generated by the crude 
oligomers in tissue culture. The common techniques employed for this purpose 
include denaturing polyacrylamide gel electrophoresis, ethanol precipitation, and 
HPLC. Electrophoresis, although a highly efficient technique, was disregarded 
because it is only suitable for small (microgram) amounts of oligonucleotide and 
because of poor recovery. Ethanol precipitation, while permitting batch-wise 
desalting of large amounts of synthetic DNA can only be performed with oligomers 
greater than 50 bases in length. HPLC, although labor intensive, was chosen 
because it yields high recovery while allowing milligram amounts of sample to be 
purified during each run. A purification system based on reverse phase 
chromatography was selected based on information supplied by Applied Biosystems 
(146). A C4 column possessing large pores (330 A) was chosen to allow maximal 
interaction between the relatively large, linear oligonucleotides (Mwt approx. 5- 
10 kD) and the column matrix.
Although all oligonucleotides were subjected to HPLC purification, 
representative chromatographic tracings of a phosphodiester (TF1) and a 
phosphorothioate (TTF6) oligomer using uV absorption as the detection system are 
shown (Fig. 24). Several comments can be made. This system is both efficient 
and sensitive as shown by the relative lack of prematurely terminated species (n- 
1-mers, n-2-mers, etc.), which appear as small peaks at the base of the single large
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Figure 24. HPLC purification of TfR antisense molecules using C4 reverse phase 
chromatography. Representative HPLC tracings of a phosphodiester 17-mer (TF1) 
and a phosphorothioate 30-mer (TTF6) and the percentage of acetonitrile (ACN) 
required for elution are shown. Detection was by uV absorption at 254 nm.
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peak which corresponds to the parental oligomer. Elution from the column was 
dependent on several factors. Oligonucleotide size and intemudeotide bond type 
were the primary determinants of the percentage of acetonitrile required for 
elution. Larger oligomers were retained longer on the column. Phosphorothioate 
sequences, which possess reduced polarity, have stronger hydrophobic interactions 
with the column matrix, hence were also retained longer. Finally, oligonucleotides 
having a higher G-C content generally eluted slower.
HPLC purification resulted in negligible changes to the electrophoretic 
pattern of oligomers (Fig. 25). As expected, there was no change in the location 
of the parental band on a polyacrylamide gel compared to oligonucleotide sizing 
markers. Moreover, the relative amounts of prematurely terminated sequences, 
represented as bands of smaller molecular weight, did not change. This indicated 
that the parental oligomer was, by far, the dominant speries and that the 
contribution of smaller incompletely polymerized oligonucleotides to the total pool 
was trivial. However, that no gross change was seen in the electrophoretic 
patterns did not exclude the removal of contaminating inorganic or organic salts 
after HPLC purification. Indeed, when fractions from an HPLC run were collected, 
lyophilized, resuspended into buffer, and added to cell cultures, a single fraction, 
which eluted well before the parental oligonucleotide, displayed potent growth 
inhibitory effects (Fig. 26). Fraction number 4, which corresponded to the first 
fraction to be eluted from the column, must contain extremely hydrophilic 
compounds. This confirmed that a low molecular weight salt(s), probably a 
blocking group involved in oligomer synthesis, was the likely contaminant.
Antisense phosphodiester oligonucleotides, which had been purified by this 
HPLC protocol, were assayed for sTfR and growth inhibition. Initial experiments 
with these molecules showed inactivity in the parental HL-60 cell line. As will be
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Figure 25. Electrophoresis of crude and purified antisense DNA. Crude and 
HPLC-purified phosphodiester oligonucleotides prepared as described in Figure 24 
legend were analyzed by 5’-end labeling, denaturing polyacrylamide gel 
electrophoresis, and autoradiography. Oligonucleotide sizing markers are shown 
at left.
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Figure 26. Toxicity of HPLC fractions of crude antisense oligodeoxynucleotides to 
HL-60 cells. 10 nmoles of crude TF1 was purified by HPLC. Fractions were 
collected at 1 min intervals, evaporated to dryness, resuspended into PBS and 
added to 200 ul serum-free ITS media with HL-60 cells (2 x 105 cells/ml). Cell 
growth was assessed after 72 hr.
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discussed below, one potential reason for this result is the presence of serum 
nucleases which rapidly hydrolyze, and thereby inactivate, phosphodiester 
oligonucleotides (105,147). For this reason, a similar set of experiments was 
conducted on an HL-60 cell line adapted to grow under serum-free culture 
conditions and generously supplied by Dr. Eric Wickstrom. At concentrations up 
to 50 uM, none of the phosphodiester antisense oligonucleotides inhibited sTfR 
expression in HL-60 cells after 24 hr of incubation (Fig. 27). Further exposure of 
cells to these oligonucleotides for 48 hr likewise did not result in any TfR 
inhibition (data not shown). Not surprisingly, growth inhibition in these cultures 
treated with oligomer was not apparent through 4 days (data not shown).
Synthesis o f and Purification o f Phosphorothioate Oligonucleotides.
That the phosphodiester oligomers proved ineffective as antisense inhibitors, 
even in the presence of serum-free medium, stimulated efforts to synthesize and 
assess oligonucleotide analogues. The phosphorothioates were selected because of 
their resistance to nuclease hydrolysis, presumed advantages in cellular uptake, 
and formation of BNA:RNA heteroduplexes which serve as substrates for RNase 
H. In addition, the chemical synthesis of these compounds is well established and 
is adaptable to conventional automated synthesizers.
The protocol used for the synthesis of these compounds is detailed in Ref. 
139, but will be briefly described here. Figure 28 shows the essential steps in the 
synthesis of these analogues. The starting reagents for the synthesis of 
phosphorothioate DNA are hydrogen-phosphonate nucleosides (Fig. 28, structure JL), 
rather than the phosphoramidate nucleosides used in the synthesis of 
phosphodiester oligomers. These precursors are activated with an acid chloride, 1- 
adamantanecarbonyl chloride (Fig. 28, structure 2), to yield a reactive intermediate
R eproduced with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
126
Figure 27. Effect of purified TfR antisense oligodeoxynucleotides on sTfR 
expression. HL-60 cells passaged in serum-free ITS medium were exposed to the 
indicated antisense oligomers at 50 uM for 24 hr. . Surface TfR levels were 
assessed by direct immunofluorescence and FACS quantitation of at least 2 x IQ4 
cells relative to vehicle-treated controls.
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Figure 28. Synthesis of phosphorothioate DNA. Scheme of single-step 
sulfurization using hydrogen phosphonate chemistry. By reaction with activating 
agent, 1-adamantanecarbonyl chloride (2), hydrogen phosphonate monomer (1) is 
converted to (3) for coupling to solid support-bound 5’-hydroxyl groups (4). Capping 
of residual hydroxyl groups and removal of the DMT protecting group (not shown) 
complete one cycle of synthesis, which when repeated ultimately affords a support- 
bound hydrogen phosphonate backbone (5) in a full-length intermediate. This 
intermediate can be either oxidized to normal DNA (6) or sulfurized to the 
phosphorothioate analogue (7). Abbreviations: A81, N6-benzoyl adenine; Gibu, N2- 
isobutyryl guanine; CBl, N1-benzoyl cytidine; T, thymidine; Et, ethyl; DMT, 
dimethoxytrityl; THF, tetrahydrofuran; Sg/CSa, elemental sulfur in carbon disulfide.
(Reprinted with permission from Elsevier Science Publishers)
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(Fig. 28, structure 3) capable of rapid coupling to the 5’-OH of a solid support- 
bound nucleoside (Fig. 28, structure 4). After the synthesis of a hydrogen- 
phosphonate oligomer with the desired base sequence is completed, the 
oligonucleotides, while still covalently bound at their 3’-OH ends to the solid 
support, are oxidized with S8 in the presence of carbon disulfide and pyridine to 
generate the intemucleotide phosphorothioate linkages (Fig. 28, structure 7). The 
phosphorothioate oligomer is then cleaved from the support using ammonium 
hydroxide. Finally, in the presence of ammonium hydroxide and heat the 
dimethoxytrityl and base protecting groups are removed to yield the final product.
The purification of phosphorothioate DNA is slightly more complex than 
that of the phosphodiester compounds. The batch-wise sulfurization step and the 
removal of the base protecting groups, which occur after the oligonucleotides are 
removed from the DNA synthesizer, generate organic and inorganic salts which 
may interfere with HPLC purification. The crude oligomers, therefore, are 
subjected to desalting by reverse phase liquid chromatography using Sep-Pak 
cartridges prior to purification by HPLC. Since phosphorothioates are more 
hydrophobic than their phosphodiester counterparts, increased levels of acetonitrile 
(24% to 30%) are required to elute these compounds from the HPLC column.
Growth Inhibition by Phosphorothioate Antisense Oligonucleotides.
Since phosphorothioate analogues are theoretically more resistant to 
enzymatic hydrolysis by serum or cellular nucleases, the biological activity of these 
oligonucleotides was assessed using the parental HL-60 cell line grown in serum- 
containing medium. A dose dependent inhibition of cellular growth was apparent 
with all of the phosphorothioate oligomers tested. After 3 days of exposure, TTF5 
exhibited the most potent biological activity. This antisense 30-mer to the
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initiation codon region inhibited cell proliferation by 80% at 50 uM (Fig. 29). 
TTF6, a scrambled sequence congener to TTF5, also inhibited HL-60 growth, but 
to a lesser degree. TTF7, a 17-mer antisense to the 5’ cap site of the TfR mRNA, 
and its scrambled sequence congener, TTF8, proved far less efficacious. In fact, 
slightly greater growth suppression was achieved with TTF8, a presumptive 
negative control, than with TTF7, the antisense sequence. The level of growth 
inhibition by all of these phosphorothioate oligonucleotides was maintained or 
slightly enhanced when cell growth was assessed after 4 days of exposure (Fig. 
30).
These preliminary results suggested that, unlike the phosphodiester 
antisense molecules, the phosphorothioate oligomers may serve as biologically active 
compounds. Although a direct investigation for an oligonucleotide length effect at 
a single target site was not performed, these results suggest that oligomers longer 
than 17-mers may be necessary for significant antisense-specific effects to be seen. 
This finding may be related to the reduced melting temperatures of DNA:RNA 
heteroduplexes consisting of phosphorothioate oligonucleotides versus those 
containing phosphodiester DNA (105). Stein et al. found that melting temperatures 
for oligonucleotide heteroduplexes were reduced by 15-20°C for phosphorothioates 
relative to phosphodiester oligomers of equal length, with the difference diminishing 
with increasing oligomer length. This observation indicated that phosphorothioate 
oligomers did not hybridize to RNA as well as did unmodified oligonucleotides. 
Thus, the use of longer oligomers, ie. 30-mers, may overcome this relative 
thermodynamic instability to promote heteroduplex complementation in the 
phosphorothioate series.
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Figure 29. Dose response of phosphorothioate oligonucleotides on HL-60 growth 
(72 hr). HL-60 cells passaged in serum-containing medium were exposed to 10 uM, 
25 uM, or 50 uM of the indicated oligomers. Cell growth was assayed after 72 
hrs.
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Figure 30. Dose response of phosphorothioate oligonucleotides on HL-60 growth 
(96 hr). HL-60 cells passaged in serum-containing medium were exposed to 10 uM, 
25 uM, or 50 uM of the indicated oligomers. Cell growth was assayed alter 96 
hrs.
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Surface TfR Inhibition by Phosphorothioate Antisense Oligonucleotides.
At 50 uM, all of the sequences tested displayed varying degrees of TfR 
inhibitory activity after only 24 hr of incubation (Pig. 31). Antisense 17-mers 
against the initiation codon (TTF1) and the cap site (TTF7) inhibited surface TfR 
expression by 50% and 75%, respectively. However, TT1S, the sense congener to 
TTF1, and TTF8, a scrambled congener of TTF7, proved to be more efficacious, 
suggesting that the inhibition may not be through an antisense mechanism. 
Although >90% receptor inhibition was achieved using 30-mer molecules, the 
antisense (TTF4 and TTF5) and scrambled sequence (TTF6) oligomers proved 
equally effective. The sTfR inhibition mediated by the oligonucleotides was not a 
transient phenomenon. Levels of sTfR continued to remain suppressed through 48 
hr in cells exposed to TTF5 and TTlS (Fig. 32).
Interestingly, a significant difference in the biological activity between 
antisense and sense oligomers was observed only with the phosphorothioate 
analogues of the c-myc 15-mer. Surface TfR expression in cells exposed to the 
antisense sequence (TMY1) were approximately five-fold lower than that of cells 
treated with the sense sequence (TMYS). Although the phosphodiester congener 
of the same sequence as TMY1 did not prevent the expression of TfR in mitogen- 
stimulated lymphocytes (93), it is not surprising that we observed receptor 
inhibition. Previous studies of the c-myc antisense phosphodiester oligomer 
reported growth arrest in HL-60 cells (91,92). TfR down-regulation at both the 
protein and mRNA levels are well-characterized events preceding the inhibition of 
proliferation in HL-60 cells (41,43,64).
Although TfR levels may decline as a consequence of cellular growth 
inhibition, the oligonucleotide-mediated inhibition of surface TfR preceded growth 
inhibition in HL-60 cells. Marked inhibition of surface TfR was observed after only
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Figure 31. Effect of phosphorothioate antisense DNA on sTfR expression in HL- 
60 cells. Cells grown in serum-containing medium were exposed to the indicated 
phosphorothioate oligonucleotides at 50 uM for 24 hr. Surface TfR levels were 
assessed as described in the legend to Fig. 6. Results represent the mean of at 
least two experiments in which the variability of individual measurements is less 
than 10% of the mean. Striped bars, 15-mers; stippled bars, 17-mers; solid bars, 
30-mers.
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Figure 32. Effect of phosphorothioate antisense DNA on sTfR expression at 24 
and 48 hr. Cells grown in serum-containing medium were exposed to the indicated 
phosphorothioate oligonucleotides at 50 uM. Surface TfR levels were assessed at 
24 and 48 hr as described in the legend to Fig. 6.
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24 hr of exposure to phosphorothioate oligonucleotides at which time there were 
no significant differences in cell number. Inhibition of growth relative to control 
cells became apparent only after 24 hr of treatment and was typically assessed 
after 72 hr.
The degree of oligonucleotide-mediated growth inhibition generally paralleled 
the level of sTfR inhibition (Fig. 33). This was seen most clearly in the series of 
anti-TfR 17-mers and the anti-myc oligonucleotides. In agreement with our 
observation that HL-60 cells express more TfR than minimally required to sustain 
growth (unpublished data), inhibition of surface TfR levels by less than 50% (TMYS 
and TTF1) resulted in negligible effects on HL-60 cellular proliferation. 
Surprisingly, although the receptor inhibitory activities between the 30-mers were 
similar, the growth inhibition achieved by the antisense oligomer (TTF5) was much 
greater than that of its scrambled sequence congener (TTF6). The reason(s) for 
this differential is unclear.
Stability of Phosphodiester and Phosphorothioate Oligonucleotides in Cell 
Culture.
To gain insight into the mechanism responsible for the differential biological 
activity seen between the antisense phosphodiester and the antisense 
phosphorothioate oligonucleotides, the nuclease susceptibility of these molecules was 
examined. A 17-mer antisense molecule (TF1) was 5’-end labeled with T4 
polynucleotide kinase and ^-A TP, incubated for up to 72 hr in fetal bovine serum 
(FBS), in heat-inactivated FBS, and with HL-60 cells grown in heat-inactivated 
FBS, and analyzed by sequencing gel electrophoresis (Fig 34). The phosphodiester 
oligomer was rapidly hydrolyzed by serum nucleases to smaller sequences, resulting 
in the appearance of a characteristic DNA "ladder." After only 4 hr in FBS, the
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Figure 33. Effect of phosphorothioate antisense DNA on HL-60 growth. Cells 
grown in serum-containing medium were exposed to 50 uM of the indicated 
phosphorothioate oligonucleotides for 3 days. Proliferation in oligomer-treated cells 
is expressed relative to vehicle-treated control cultures. Results represent the 
mean ± S.D. of at least three experiments except in the cases of TMY1, TMYS, 
and TTF1, which represent the mean of two experiments. Striped bars, 15-mers; 
stippled bars, 17-mers; solid bars, 30-mers.
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Figure 34. Stability of phosphodiester antisense DNA in culture media. TF1 
oligonucleotide was 5’-end labeled with [“PJATP and incubated at 37°C for the 
indicated periods of time in RPMI 1640 medium with 15% FBS, 15% heat- 
inactivated (HI) FBS, or 15% HI-FBS + HL-60 cells. Oligomer stability was 
evaluated by polyacrylamide gel electrophoresis and autoradiography. 
Oligonucleotide sizing markers are shown at right.
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undigested 17-mer was completely absent, with the majority of remaining oligomer 
being in the 13- to 15-mer length range. In contrast, heat-inactivation of serum 
abolished this endogenous nuclease activity and the parental 17-mer was stable 
through 24 hr. The addition of proliferating HL-60 cells to medium containing 
heat-inactivated serum resulted in the appearance of a nuclease activity different 
from that seen in serum alone. This presumed cell-associated nuclease activity 
displayed slower kinetics of hydrolysis and appeared to be an endonuclease by the 
absence of a discrete DNA ladder. A 5’-phosphatase was apparently endogenous 
to FBS and/or elaborated by HL-60 cells as evidenced by the temporal loss of total 
“T* signal associated with oligomers.
Heat-inactivated fetal bovine sera are commercially available. To determine 
whether significant differences in the levels of nuclease activities existed between 
commercially supplied heat-inactivated FBS versus that prepared in the laboratory, 
these were assayed in the system described above. A commercial preparation of 
Hl-serum (GIBCO) was tested against a lot of serum (Sigma) treated at 65°C for 
30 min. 5’-End labeled oligonucleotide (TF1) was rapidly hydrolyzed in the GIBCO 
preparation as shown by the appearance of a DNA ladder after as little as 1 hr 
(Fig. 35A). To a first approximation, this preparation contained similar levels of 
nuclease activity as that in serum which had not been manually heat-inactivated 
at all (compare with Fig. 34). In contrast, manual heat-inactivation served to 
substantially eliminate nuclease activity during the assay period as shown by the 
retention of the parental oligomer band and delay in the appearance of a DNA 
ladder until 12 hr (Fig. 35B). Increased hydrolysis of TFl was seen at 24 hr in 
Figure 35B versus Figure 34 because the oligomer was incubated in 100% serum 
in the former versus 15% serum in the latter. Clearly, not all heat-inactivated 
sera are created equally, at least with respect to nuclease activity.
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Figure 35. Stability of phosphodiester antisense DNA in heat-inactivated serums. 
TF1 oligonucleotide was 5’-end labeled with [^JATP and incubated at 37°C for the 
indicated periods of time in 100% serum. Oligomer stability was evaluated by 
polyacrylamide gel electrophoresis and autoradiography. Oligonucleotide sizing 
markers are shown for reference.
A: Commercially prepared heat-inactivated fetal bovine serum from GIBCO.
B: Fetal bovine serum from Sigma which had been heat-inactivated at 65°C for 
30 min in the laboratory.
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In contrast, modification of the same sequence with phosphorothioate groups 
at each intemucleoside linkage (TTF1) resulted in marked resistance to serum 
nuclease hydrolysis (Fig. 36). No degradation in FBS was seen through 10 hr as 
judged by the absence of a DNA ladder. It was unclear whether further incubation 
with serum resulted in nuclease hydrolysis because a serum-derived 5-phosphatase 
activity, presumably similar to that seen in Figure 34, removed the label from 
the parental oligonucleotide, resulting in a gradual attenuation of the 17-mer 
signal. This interpretation was supported by the lack of non-enzymatic hydrolysis 
or loss of the label when TTF1 was incubated in ITS medium for 96 hr.
Finally, the phosphorothioates demonstrated complete resistance to cell- 
elaborated nucleases through 48 hr of culture in serum-free medium in which 
serum-derived nucleases and phosphatases were absent (Fig. 37). Interestingly, 
the phosphodiester oligonucleotide, TF1, also showed absolute resistance to 
hydrolysis by cell-elaborated nucleases when cultured under the same conditions 
in ITS medium. In summary, these findings suggest that markedly different 
nuclease sensitivities between the phosphorothioates and the phosphodiesters may 
permit biological efficacy as antisense agents in the former. In addition, it appears 
possible to obviate the need for heat-inactivated serum or serum-free medium 
formulations when exposing cells to phosphorothioates in culture. These results, 
therefore, suggests that a primary reason for increased biological activity seen with 
the phosphorothioate oligonucleotides is increased survival in tissue culture through 
enhanced resistance to serum and/or cellular nucleases.
Cellular Uptake of Phosphodiester and Phosphorothioate Oligonucleotides.
Another postulated advantage of phosphorothioate oligomers as antisense 
molecules is enhanced cellular uptake owing to diminished anionic charge density
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Figure 36. Stability of phosphorothioate oligomers in sera and ITS. TTF1 
oligonucleotide was 5’-end labeled and incubated at 37°C for the indicated intervals 
in RPMI1640 medium with 15% FBS or with an insulin-transferrin-selenium (ITS) 
serum-free substitute. Oligomer stability was evaluated by polyacrylamide gel 
electrophoresis and autoradiography. Oligonucleotide sizing markers are shown for 
reference.
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Figure 37. Stability of phosphodiester and phosphorothioate oligomers in the 
presence of cells in ITS. TF1 or TTF1 was 5’*end labeled and incubated at 37°C 
for the indicated intervals with HL-60 cells in RPMI 1640 medium + ITS. 
Oligomer stability was evaluated by polyacrylamide gel electrophoresis and 
autoradiography. Oligonucleotide sizing markers are shown at left.
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at each intemucleotide linkage. The anionic nature of the phosphodiester bond 
has been theorized to inhibit oligonucleotide uptake through the hydrophobic cell 
membrane (103). Whether this is actually the case is still in question as 
quantitative comparisons between the uptake of different classes of antisense 
oligonucleotides possessing identical sequences have not been reported. For this 
reason, we attempted to compare the cellular uptake of a phosphodiester 
oligonucleotide (T1S) with its phosphorothioate congener (TT1S).
In order to perform quantitatively relevant comparisons of oligonucleotide 
uptake into whole cells, 5’-end labeled oligomers must first be separated from any 
unincorporated S2P-ATP in the reaction mixture such that the specific activity of 
the preparations may be determined. Sep-Pak reverse phase cartridges were 
employed as a convenient method to accomplish this level of purification. In 
agreement with the unpublished observations of G. Zon, the 5’-OH from 
phosphodiester oligomers served as a more efficient substrate for T4 polynucleotide 
kinase than that from phosphorothioate oligomers. More of the radiolabel became 
incorporated with unmodified oligonucleotide than with the phosphorothioate 
counterpart (Fig. 38). The specific activity of ^-labeled T1S was four times that 
of ^-labeled TT1S.
Initial experiments focused on the association of radiolabeled oligomer with 
HL-60 cells under physiological conditions. The use of cells grown in serum-free 
ITS medium obviated the necessity to correct for any extracellular 5’-phosphatase 
or serum derived-nuclease activities which may degenerate the radiolabeled 
parental oligomer and, thereby, complicate the analysis of uptake kinetics. After 
incubation with oligomer for varying periods of time, cells were layered over chilled 
oil and centrifuged. The residual aqueous and oil layers were removed by 
aspiration, and the cell pellets quantified for cell-associated signal. It must be
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Figure 38. Purification of 5’-end labeled oligonucleotides. Two nmoles of oligomer 
(T1S or TT1S) were 5’-end labeled with 3 U of T4 polynucleotide kinase and 66 
pmoles of “T-gamma ATP (200 uCi) at 37°C for 90 min. After boiling for 5 min, 
samples were suspended into 0.2 ml of 10 mM NH4OAc. Sep-Pak cartridges were 
pre-equilibrated with acetonitrile (ACN), followed by 10 mM NH4OAc. Samples 
were loaded onto the columns, followed by flushing of columns with 7 ml of 10 mM 
NH4OAc and 5 ml of air. Samples were eluted with 3 ml of 25% ACN in water 
(T1S) or 75% ACN in water (TT1S). Finally, columns were washed with 1 ml of 
100% ACN. Column fractions of 1 ml each were collected and the radioactivity 
quantitated by liquid scintillation spectrometry. Abbreviations: FT, flow-through; 
W, wash; E, elution.
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emphasized that this represents an overestimate of cellular uptake, as one cannot 
differentiate between oligonucleotides that are loosely associated with the cell 
membrane versus those than are actually within the cytoplasm and/or nucleus. 
With these qualifications in mind, the characteristics of cell-association of the 
phosphorothioate oligomer, TT1S, showed saturable kinetics through 2 hr (Fig. 39).
In order to determine the fraction of total cell-associated oligomer that had 
been internalized, cells were additionally washed with either 0.2 M glycine or 0.2 
M acetic acid and 0.5 M NaCl (140). This step removes macromolecules loosely 
associated with the external face of the plasma membrane, but does not affect 
internalized ligands. Cells that had been add-washed contained approximately 6- 
fold lower levels of TT1S than untreated cells (Fig. 40). This suggested that a 
significant fraction of oligonucleotides remained at or near the extracellular face 
of the plasma membrane. The rapid and saturable nature of uptake kinetics was, 
however, unchanged by acid-washing. Apparent maximal levels of phosphorothioate 
oligonucleotide uptake were achieved after only 1 hr. It remained possible, 
however, that the presence of intracellular 5’-phosphatases may have lowered the 
specific activity of internalized oligomers such that these results represented 
underestimates of the actual cellular accumulation.
The uptake of TT1S, a phosphorothioate oligomer, was dramatically different 
from that seen with T1S, its phosphodiester congener. Phosphorothioate DNA 
exhibited rapid and saturable uptake kinetics, with plateau levels being observed 
after approximately 60 min of incubation (Fig. 41). In contrast, the same sequence 
in the phosphodiester series exhibited extremely slow, essentially linear uptake 
through 6 hr after which total oligonucleotide uptake was 40-fold less than that 
seen with the phosphorothioate.
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Figure 39. Cell-association of phosphorothioate DNA. 5’-End labeled TT1S was 
incubated at 37°C with HL-60 cells in RPM I1640 medium + ITS. At the indicated 
times, cells were collected, layered over chilled oil, and centrifuged. Radioactivity 
associated with the cell pellets was immediately assessed by liquid scintillation 
spectrometry. Values represent the mean * S.D of 3 separate experiments.
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Figure 40. Cellular uptake of phosphorothioate DNA. 5’-End labeled TT1S was 
incubated at 37°C with HL-60 cells in RPMI 1640 medium + ITS. At the indicated 
times, cells were collected, layered over chilled oil and centrifuged. After the 
aqueous and oil layers were removed by aspiration, radioactivity associated with 
the cell pellets was immediately assessed by liquid scintillation spectrometry and 
after a 5 min acid wash at 4°C. Cell-associated radioactivity remaining after acid- 
washing was considered to represent internalized oligonucleotides. Values 
represent the mean ± S.D of triplicate samples.
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Figure 41. Cellular uptake of phosphorothioate vs. phosphodiester DNA. 5’-End 
labeled oligonucleotides (T1S or TT1S) were incubated at 37°C with HL-60 cells in 
RPMI 1640 medium + ITS. At the indicated times, cells were collected, layered 
over chilled oil and centrifuged. After the aqueous and oil layers were removed 
by aspiration, radioactivity associated with the cell pellets was immediately 
assessed by liquid scintillation spectrometry and after a 5 min acid wash at 4°C. 
Cell-associated radioactivity remaining after acid-washing was considered to 
represent internalized oligonucleotides. ®, TT1S; □ , T1S. Dotted lines represent 
samples not acid washed; solid lines represent acid-washed samples. Values 
represent the mean ± S.D of triplicate samples.






R e p ro d u c e d  with perm iss ion  of th e  copyright ow ner.  F u r th e r  reproduction  prohibited without perm iss ion .
165
Oligonucleotide uptake into eukaryotic cells is difficult to evaluate given the 
limitations of experimental techniques. Studies involving oligonucleotides 
containing covalently-linked fluorescent probes, ie. acridine, suffer from the 
possibility that the cellular uptake and dispersion of derivatized oligonucleotide 
may be artifactually altered by the fluorescent moiety. For this reason, our 
experiments were conducted with radiolabeled oligonucleotides. However, the 
conclusions drawn from these experiments are predicated upon the assumption that 
the 32P signal remaining after acid-washing of cells represents intact parental 
oligonucleotide. Although the phosphorothioate TTFl was shown to be resistant 
to degradation by nucleases secreted from HL-60 cells (see Fig. 37), it is within the 
realm of speculation that phosphorothioate DNA is sensitive nucleases contained 
within the cell. Hence, the resultant internalized signal may not represent 
oligonucleotide which is biologically active as an antisense agent.
It is also conceivable that the removal of the S2P label from oligonucleotides 
by intracellular phosphatases may have resulted in an underestimate of the 
amount of oligomers accumulated. The complicating effects of any serum-derived 
phosphatases have, however, been eliminated in our experiments through the use 
of serum-free medium. Ideally, it would be preferable to measure the cellular 
uptake of the intact parental oligonucleotide. This could be performed by 
evaluating for the presence of the intact parental oligonucleotide in whole cell 
lysates by denaturing polyacrylamide gel electrophoresis. Nevertheless, these 
results represent the first attempt at quantitative comparison of the cellular 
accumulation of identical antisense oligomers of the phosphodiester and 
phosphorothioate series and confirm the theoretical advantage in cellular uptake 
ascribed to the decreased polarity of the phosphorothioate bond.
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The enhanced cellular uptake of the phosphorothioate oligonucleotides may, 
therefore, represent a second reason for the increased biological efficacy of these 
compounds over the phosphodiester oligomers as antisense inhibitors.
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These experiments have characterized the biosynthetic regulation of the 
transferrin receptor in chemically differentiating HL-60 leukemia cells and have 
demonstrated that sTfR can be modulated using antisense phosphorothioate 
oligodeoxynucleotides (63,64,148). Using dot blot analyses, we showed that 
exposure of HL-60 cells to DMSO induced a specific decrease in TfR mRNA within 
the first 24 hrs and that this effect preceded both the down-regulation of surface 
receptors and decreased cell proliferation as well as the appearance of the mature 
phenotype (63). We then corroborated this phenomenon using northern blot 
analysis, which permitted molecular size verification that hybridized mRNAs 
represented the transcripts of interest and that contaminating species contributed 
little to the overall signal (64). The kinetics of the BMSO-induced decrease in TfR 
message, as assessed by either dot blot or northern blot techniques, were similar 
after 12 hrs of treatment, with a 50% reduction in receptor message seen. A 
comparison of the kinetics of sTfR protein and transcript levels, along with our 
demonstration that DMSO did not induce a reduction in the half-life of the mature 
sTfR protein, provide compelling evidence that the down-regulation of TfR during 
the DMSO-induced differentiation of HL-60 cells is mediated at the mRNA level. 
Confirming our initial studies, transcriptional down-regulation of the TfR gene 
during chemically-induced differentiation was demonstrated by other groups (65,66) 
using the technique of nuclear run-off studies in HL-60 cells.
We have also demonstrated that a reduction in steady-state TfR mRNA is 
a feature common to the chemical induction of HL-60 cell differentiation by a 
variety of structurally dissimilar agents. The reduction in TfR mRNA did not 
appear to be secondarily related to decreased nuclear transcriptional activity, since
167
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appreciable changes in *H-uridine incorporation and in the steady-state levels of 
fi-actin transcripts or ribosomal KNA did not occur during the first 24 hrs of 
exposure to inducers. This effect on the TfR was not a metabolic consequence 
specific to the action of DMSO, since other myeloid inducers with disparate 
intracellular actions, including ACM and RA, caused similar reductions. 
Furthermore, the biosynthetic modulation of the TfR was not restricted to a 
particular cell lineage, since HL-60 cells induced to differentiate along the 
macrophagic pathway hy TPA also demonstrated decreased receptor transcripts. 
Taken together, these observations suggest that down-regulation of TfR transcripts 
is a fundamental feature in the chemical induction of HL-60 cell differentiation.
In addition, TfR expression appears to be an important general process in 
the differentiation of leukemic cells, as receptor down-regulation was also observed 
with the Ml and K562 leukemias (46,47). In contrast to these effects, Friend 
erythroleukemia cells have been shown to express 3- and 6*fold increases in 
cellular TfR after 3 and 5 days, respectively, of DMSQ-induced erythroid 
differentiation (48). This difference in TfR metabolism between myeloid leukemia 
and erythroleukemia cells appears to be due to the increased biochemical 
requirement for iron in the synthesis of hemoglobin in mature reticulocytes. In 
addition, cellular enucleation serves as a distinct mechanism for terminating 
replication in erythroid differentiation. Thus, the increase in transferrin-TfR 
activity in Friend erythroleukemia cells is obligatory for the expression of the 
mature erythroid phenotype.
Terminal differentiation, by definition, involves both the programmed 
cessation of proliferation and the acquisition of a mature phenotype. The 
relationship of these two pathways remains to be determined. Since TfR 
expression is enhanced by the stimulation of cellular proliferation in other systems
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(45), reductions in TfR mRNA and protein biosynthesis may be viewed as a 
consequence of growth inhibition and, therefore, be unrelated to differentiation per 
se. Indeed, untreated HL-60 cells in plateau phase growth exhibited pronounced 
reductions in sTfH to levels analogous to those seen with terminally differentiated 
cells. The kinetics of TfR down-regulation in differentiating cells, however, differs 
markedly, depending upon the inducer employed. Nevertheless, a significant 
temporal relationship exists between the degree of surface receptor down-regulation 
and the eventual inhibition of growth. Thus, we have observed a complete 
cessation of cellular proliferation within 10 to 16 hrs after induced cells expressed 
a four-fold decrease in sTfR. Cells induced to mature with la,25-dihydroxyvitamin 
D3, however, did not down-regulate sTfR to this degree. Accordingly, these cells 
expressed no growth inhibition relative to uninduced cells.
Corroborating evidence for this hypothesis was provided by experiments with 
exogenous iron or the iron chelator, deferrioxamine. Attempts to manipulate iron 
availability in parallel or in opposition to that resulting from TfR down-regulation 
resulted in alterations to cellular proliferation, without attendent effects on cellular 
maturation. Modulation of TfR activity is clearly not a simple consequence of the 
termination of growth, since down-regulation was always seen prior to the cessation 
of proliferation and the appearance of significant alterations in the cell cycle 
profiles of induced cells. Thus, these findings suggest that TfR down-regulation 
may be involved in signalling a programmed inhibition of growth which is requisite 
for terminal differentiation.
It is intriguing that a conflicting trend exists between sTfR and intracellular 
transcript levels during the initial 12 hrs of TP A induction. We interpret the 
maintenance of unchanged levels of total cellular TfR reported by others (50) 
concommitant with the increasing amounts of TfR message which we observe in
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TPA-treated cells (64) to suggest another potential mode of regulation in the 
biosynthesis of this receptor. The findings suggest that normal regulation of TfR 
biosynthesis is uncoupled, whereby newly synthesized transcripts are not 
translated. Conceivably, phorbol esters may induce modulations in the cellular 
translational apparatus which reduce recognition of TfR transcripts. Alternatively, 
intrinsic alterations in the mRNA, such as additions, deletions, or splicing, which 
do not appreciably change message size and, hence, are undetectable by probe 
hybridization cannot be excluded. Future experiments should investigate the 
molecular mechanism(s) behind this newly observed phenomenon.
The mechanisms by which the differentiation inducers, TP A and ACM, 
modulate sTfR levels in HL-60 cells have been previously demonstrated to involve 
protein phosphorylation and glycosylation, respectively. The phorbol esters alter 
the cellular distribution of the receptor by promoting a rapid (tV6=60 min) 
internalization of membrane associated TfR, a phenomenon correlated with 
phosphorylation of the protein at serine residues by protein kinase C (50,52). The 
anthracyclines, ACM and marcellomycin, appear to reduce transferrin binding by 
inhibiting glycosylation during the biosynthesis of the receptor (49). We now 
demonstrate that TP A and ACM act via an additional mechanism to decrease 
steady-state levels of TfR message.
Our results are consistent with the hypothesis that a down-regulation of the 
sTfR mediates the cessation of proliferation in differentiating HL-60 cells. This 
may be partly due to a reduction in TfR transcription during granulocytic 
differentiation. Surface TfR internalization is rapidly promoted during TPA- 
induced monocytic differentiation, hence an increase in transcript levels does not 
significantly influence the initial decrease in receptor activity. Whether this is a 
feature of monocytic differentiation or a specific consequence of the stimulation of
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protein kinase C by TPA is unresolved. However, a drastic decline in the level of 
steady-state message does contribute to the maintenance of diminished TfR in cells 
differentiated by TPA.
The process of terminal differentiation is complex, with a multitude of 
requisite cellular alterations occurring with differing kinetics. In addition, the 
diversity of agents capable of inducing differentiation implies that numerous 
intracellular targets exist which may transmit the initiating signal(s). Ultimately, 
alterations in nuclear activity must occur in order to commit cells to a 
differentiation pathway and to maintain the mature phenotype. The TfR appears 
to be an important component of the genetic changes underlying leukemic cell 
differentiation; however, its precise role within this framework of cellular mediators 
and processes critical to the maturation process remains to be fully elucidated.
One potential strategy to probe the role of TfR in leukemia cell 
differentiation involves the use of more specific agents which, ideally, modulate the 
cellular homeostasis of TfR, but lack disparate biochemical activities within the 
cell. Antisense oligodeoxynucleotides have emerged as novel and specific inhibitors 
of gene expression, thus seem uniquely suited for this purpose. This field was 
pioneered by the work of Zamecnik and Stephenson (74,75) who, in 1978, described 
the inhibition of Rous sarcoma virus replication by a tridecamer (13-mer) 
complementary to terminal repeat sequences of the viral 35S RNA. Since then, 
this strategy has been applied in a variety of eukaryotic and viral systems against 
disparate cellular targets, including z-myc (91-94), c-myb (95-97), c-mos (149), B- 
globin (107), cyclin (98), dihyrofolate reductase (99), herpes simplex virus type 1 
(114,118), and human immunodeficiency virus (HIV) type 1 (112,113,116-120,150).
The early studies with antisense DNA were limited to first generation 
oligodeoxynucleotides possessing internucleoside phosphodiester linkages similar to
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that of native DNA. HL-60, a human promyelocytic leukemia cell line, has served 
as a convenient model system for many of the early antisense studies. Wickstrom 
et al. (91) employed a pentadecamer (15-mer) complementary to the initiation codon 
region of the c-myc oncogene; at 10 uM, this oligomer inhibited myc protein 
expression as detected by both immunofluorescence and by immunoprecipitation. 
Furthermore, cell proliferation was inhibited in a dose-dependent and sequence- 
specific manner, and antisense pentadecamers to the vesicular stomatitis virus 
(VSV) and to the HIV tat gene were without effect on myc expression. Further 
work by this group demonstrated that this anti-myc 15-mer induced NBT activity, 
morphological maturation consistent with granulocytic differentiation, and reduced 
colony formation in soft agar (151). Using the same system, Holt et al. (92) 
similarly demonstrated that the anti-myc oligonucleotide induced granulocytic 
differentiation in approximately 30% of cells after 3 days of treatment. These 
results, however, contrasted with previous reports in which antisense RNA to myc 
induced monocytic differentiation (88).
We have demonstrated that phosphorothioate antisense oligonucleotides are 
more efficacious than their phosphodiester counterparts as inhibitors of TfR 
expression in HL-60 leukemia cells. The degree of receptor suppression was 
dependent upon oligomer length with 30-mer compounds uniformly displaying 
greater activity than 17-mers. However, the effects seen with the anti-TfR 
oligonucleotides could not be fully ascribed to antisense mechanisms, since sense 
oligomers and those in which the base sequence was partially scrambled 
consistently showed equivalent or greater activity than their antisense counterparts. 
In general, the degree of oligonucleotide-mediated growth inhibition was 
proportional to the decrease in receptor levels. An interesting exception occurred 
with the antisense 30-mer, TTF5, and its scrambled sequence congener, TTF6.
R e p ro d u c e d  with perm iss ion  of th e  copyright ow ner.  F u r the r  reproduction  prohibited without perm iss ion .
173
Whereas both inhibited sTfR expression to a similar degree, the antisense sequence 
TTF5 was nearly twice as efficacious as TTF6 in suppressing cellular growth.
The reason(s) underlying this observation remains to be determined. 
However, that TTF5 and TTF6 are 30-mers may have significance. Heteroduplexes 
formed between polyribonucleotides and phosphorothioate oligomers have melting 
temperatures approximately 15-20°C lower relative to those formed using 
phosphodiester oligomers of equal length (105). This difference diminished with 
increasing oligonucleotide length. This relative thermodynamic instability of 
complementation results in the theoretical need to employ longer sequences to 
achieve similar levels of heteroduplex formation as that accomplished by shorter 
sequences of phosphodiester oligonucleotides. Interestingly, a heteroduplex of poly- 
tA and a phosphorothioate dT-homooligomer of 28 bases had a melting temperature 
of 36°C (105). Thus, the phosphorothioate 30-mers, in contrast with the 17-mers, 
may be of a sufficient length to bind by an antisense mechanism to TfR mRNA at 
physiological temperatures, thereby permitting distinction between the biological 
activities of antisense versus sense or missense sequences.
A high concentration (50 uM) of oligonucleotides was selected for use during 
these in-vitro studies. It is conceivable that elevated concentrations of 
phosphorothioate oligonucleotides have "toxic", ie. antisense-independent, effects on 
cellular targets. At lower concentrations, the antisense effects predominate and 
biological activity would correlate with sequence specificity. At higher 
concentrations, however, antisense-independent activities, which have not been fully 
characterized, may emerge. This titration between predicted and unpredicated 
cellular activities may result in the appearance of a sequence-independent 
phenomenon. Hence, our inability to demonstrate an antisense-specific suppression 
of sTfR by phosphorothioate oligonucleotides may also be explained if receptor
R e p ro d u c e d  with p erm iss ion  of th e  copyright ow ner.  F u r the r  reproduction  prohibited without perm iss ion .
174
inhibition is a manifestation of toxicity by these compounds. Since the antisense 
sequence TTF5 inhibits cellular growth better than its scrambled sequence congener 
TTF6, this suggests that antisense mechanisms are operative, as least in part. 
The evaluation of these oligonucleotides at lower concentrations, where these 
sequence-independent toxicities are less prevalent, may help to verify this 
hypothesis.
Antisense mediated TfR and growth inhibition also occurred using an anti- 
myc phosphorothioate 15-mer. Since enhanced c-myc expression is related to 
increased cellular proliferation, it is not surprising that inhibition of c-myc led to 
interference with growth and the expression of TfR. It is a reasonable postulate 
that the anti-myc phosphorothioate oligomer may not act directly to inhibit the 
expression of the TfR gene. Rather, the presumed inhibition of c-myc expression 
in these cells may result in the propagation of intracellular signals which act to 
suppress proliferation. This, in turn, would result in a decreast in sTfR activity 
since non-replicating cells have reduced iron uptake requirements.
The precise mechanism(s) by which phosphorothioate oligonucleotides exert 
gene inhibitory activity within the cell remains unclear. Consistent with classical 
antisense theory, the phosphorothioates have been shown to bind to single-strand 
RNA, forming heteroduplexes which may Berve as substrates for RNase H 
degradation (107,121). However, sequence-independent actions of the 
phosphorothioate oligonucleotides are pleiotropic and have been well documented. 
For example, Matsukura et al. (117) showed that a 28-mer phosphorothioate 
oligodeoxycytidine homooligomer (S-dC^) inhibited the cytopathic effect of HIV by 
direct interference with the retroviral reverse transcriptase. Interestingly, in 
agreement with our results, phosphorothioate inhibition of HIV activity was 
dependent upon length, with 28-mers being more potent than 14-mers; 5-mers
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showed no activity. In an analogous manner, S-dC^ was found to be a competitive 
inhibitor of HSV type 2 DNA polymerase, but interfered with human DNA 
polymerases less effectively (118). Finally, the inhibition of HIV replication by 
cholesteryl-conjugated oligonucleotides did not correlate with a specific antisense 
sequence, suggesting an action other than an antisense mechanism may be 
operative (152). Our findings support the concept that phosphorothioate 
oligonucleotides may express biological activities independent of conventional 
antisense gene inhibition.
We have demonstrated that the enhanced nuclease resistance and cellular 
uptake ascribed to the phosphorothioate oligonucleotides may be involved in their 
increased biological efficacy over their phosphodiester counterparts. Others have 
previously described this phenomenon using purified enzymes (105,153) and serum 
(147). Stein et al. found that phosphorothioate oligomers were more resistant to 
hydrolysis by endonuclease SI, the exo- and endonuclease PI, and snake venom 
phosphodiesterase by 40-fold, 20-fold, and 2000-fold, respectively (105). Spitzer and 
Eckstein determined that phosphorothioate oligomers were more resistant to 
hydrolysis by staphylococcal nuclease and spleen phosphodiesterase by 10-fold and 
100-fold, respectively; the phosphorothioate oligonucleotides were completely 
resistant to degradation by pancreatic DNase I and spleen DNase II (153). We 
have extended these observations by directly comparing biological activity with 
serum and cellular nuclease susceptibility using identical sequence oligomers of the 
phosphodiester (TF1) and phosphorothioate (TTF1) series.
For biological activity to be expressed, antisense oligonucleotides must 
traverse the plasma membrane of cells. The mechanism by which cells accumulate 
oligomers from the extracellular environment is still unclear. Loke et al. 
determined that the cellular uptake of antisense DNA is a saturable and size-
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dependent process compatible with receptor-mediated endocytosis (154). 
Furthermore, by using oligo-dT cellulose for affinity purification, this group 
identified an 80 kD surface protein from HL-60 cells which may mediate this 
transport process. Similarly, Yakubov et al. found that 69 kD and 90 kD 
membrane proteins from mouse fibroblasts could be cross-linked to radiolabeled 
phosphodiester oligonucleotides (155). That the uptake of phosphodiester oligomers 
by this mechanism was competed by phosphorothioates suggests that these two 
classes of oligonucleotides may share this uptake mechanism (154). Our finding 
of rapid and saturable uptake kinetics is consistent with this model for cellular 
uptake. Furthermore, our results represent the first quantitative comparison of the 
cellular accumulation of identical antisen3e oligomers of the phosphodiester and the 
phosphorothioate series and confirm the theoretical advantage in cellular uptake 
ascribed to the decreased polarity of the phosphorothioate bond.
In summary, phosphorothioate oligonucleotides were uniformly more 
efficacious than their unmodified phosphodiester counterparts as inhibitors of TfR 
expression and proliferation in HL-60 cells in culture. A greater resistance to 
hydrolysis by serum and cellular nucleases and more efficacious cellular uptake of 
the phosphorothioate analogues in comparison to their phosphodiester counterparts 
appeared to contribute to their greater biological activity. The means of inhibition 
of gene expression by the phosphorothioates in this eukaryotic system may, 
however, involve pleiotropic mechanisms independent of antisense complementary 
binding to mRNA. Thus, the findings support recent reports that the antiviral 
activity of phosphorothioate oligonucleotides may involve other cellular targets in 
addition to viral transcripts. Further efforts to delineate the intracellular actions 
of the phosphorothioates will be required before the therapeutic potential of these 
compounds as antitumor or antiviral agents can be fully assessed.
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1. Transferrin receptor down-regulation which occurs during granulocytic 
differentiation by dimethyl sulfoxide, retinoic acid, or aclacinomycin A 
appears to be kinetically compatible with reduced biosynthesis resulting from 
reductions in the level of steady state mRNA (Figures 7,9-11; Tables 3,4).
2. In contrast, biosynthetic modulation does not appear to mediate the initial 
receptor down-regulation seen during TPA-induced macrophagic 
differentiation. However, a reduction in the levels of receptor mRNA 
appears to contribute to the maintenance of diminished TfR activity in these 
TPA-treated cells (Figures 7,9; Table 3).
3. The kinetics of sTfR down-regulation in differentiating cells differs markedly 
depending upon the inducer used. Nevertheless, a significant temporal 
relationship exists between the degree of receptor down-regulation and the 
eventual inhibition of growth (Figures 3,7,12,14). A complete cessation of 
cellular proliferation is observed within 10 to 16 h after induced cells 
expressed a 4-fold reduction in sTfR (Table 2). Additionally, the 
manipulation of extracellular iron levels markedly modulated the cellular 
growth of uninduced and induced cells without attendent effects on cellular 
maturation, either alone or in concert with DMSO or RA (Figures 17,18). 
These findings suggest that TfR down-regulation may be involved in the 
signaling a programmed inhibition of growth which is requisite for terminal 
differentiation.
177
R e p ro d u c e d  with perm iss ion  of th e  copyright ow ner.  F u r th e r  reproduction  prohibited without perm iss ion .
178
4. Phosphorothioate anti-TfR antisense oligonucleotides exhibited marked 
biological efficacy in culture, as assessed by inhibition of surface TfR content 
and HL-60 growth, whereas their unmodified phosphodiester counterparts 
were ineffective (Figures 27, 29-33).
5. A length effect was observed, with antisense 30-mers exhibiting greater TfR 
inhibitory activity than 17-mers (Figures 31,33). The degree of receptor 
inhibition observed, however, was not strictly sequence dependent, suggesting 
that the phosphorothioate oligonucleotides may have pleiotropic activities in 
eukaryotic cells in addition to inhibiting gene expression by presumptive 
antisense complementary binding to mRNA.
6. Phosphorothioate oligonucleotides were more resistant to hydrolysis by serum 
and cellular nucleases (Figures 34,36,37), and were more readily taken up 
by cells than phosphodiester oligonucleotides (Figures 41), thus providing a 
partial explanation for the differences in biological activity.
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